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 Colon cancer is one of the leading causes of cancer mortality in the developed 
world. Evidence from epidemiological and animal studies indicates that the n-3 
polyunsaturated fatty acids (PUFAs) may protect against colon cancer. However the 
mechanisms of the anti-cancer effects of n-3 PUFAs have not been fully elucidated. 
Docosahexanoic acid (DHA) (22:6, n-3), abundantly found in fish oil, is one of the 
principal n-3 PUFAs. The aims of this study were (i) to investigate the effects of the n-3 
PUFAs, and DHA in particular, on cell growth and apoptosis in colon cancer cell lines 
(ii) to explore the signaling pathways responsible for the chemotherapeutic and 
chemopreventive actions of DHA. 
 The growth inhibitory effects of DHA were demonstrated by the MTT assay. 
DHA was more potent in inhibiting growth than the n-6 PUFAs, monounsaturated and 
saturated fatty acids. The cytotoxic effect of DHA was due to apoptosis, as demonstrated 
by nuclear condensation, sub-G1 assay and PARP cleavage. DHA also activated caspase-
3; and the caspase inhibitor z-VAD-fmk was able to block the DHA-induced apoptosis. 
 The effect of DHA on the mitogen-activated signaling kinases (MAPKs) was also 
investigated. DHA activated JNK, ERK and p38 MAPKs. The activation of JNK played a 
key role in the apoptotic action of DHA, as inhibition of JNK either by the specific JNK 
inhibitor SP600125 or by overexpression of the dominant-negative mutants of JNK 
significantly repressed both the JNK activity and apoptosis induced by DHA. It was 
further shown that DHA induces oxidative stress but the JNK activity and apoptosis were 
independent of the reactive oxygen species generation.  
 xi
 DHA also induced the transcriptional activity of the Peroxisome Proliferator-
activated receptor γ (PPARγ). Activation of ERK interfered with ability of DHA to 
activate PPARγ. DHA also inhibited TNF-α – induced COX-2 expression and NF-κB 
activation. This inhibition was dependent on PPARγ as repressing the PPARγ expression 
by transfection of antisense PPARγ oligonucleotides, decreased the inhibitory effect of 
DHA on COX-2 expression. However, there were no significant changes in cell death 
when PPARγ was inhibited, indicating the possibility that DHA induced apoptosis 
through PPARγ-independent pathway. 
 In conclusion, this study provides an insight into the pathways involved in the role 
of DHA in colon cancer. This study for the first time shows (i) activation of JNK plays a 
key role in DHA-induced apoptosis (ii) DHA inhibits COX-2 by the activation of PPARγ. 
Thus, different mechanisms seem to be involved in the anti-carcinogenic effect of DHA 




















































1.1 Polyunsaturated Fatty Acids 
 
 Polyunsaturated fatty acids (PUFAs) are ubiquitious biological molecules that 
function as metabolic fuels, as covalent regulators of signaling molecules, and as 
essential components of cellular membranes. However, alongside these essential 
functions, fatty acids have also been identified as having an effect, both positive as well 
as negative, on health and disease progression.  
 
1.1.1 Structure 
 Fats form a large group, composed of different types of fatty acids and glycerol. 
Fatty acids are hydrocarbon chains with a carboxyl group at one end. Fatty acids usually 
contain an even number of carbon atoms and on the basis of their degree of saturation, 
can be classified into saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) 
(with one double bond), and polyunsaturated fatty acids, PUFAs (with multiple double 
bonds). According to conventional nomenclature of fatty acid molecules, PUFAs are 
classified into different groups on the basis of the position of the first double bond from 
the methyl terminus of the hydrocarbon chain of the molecule. Thus n-3 and n-6 PUFAs 
are so named as they have their first double bond at the 3rd and 6th carbon respectively 
(Nettleton, 1995). 
 
1.1.2 Synthesis of n-3 and n-6 PUFAs 
 Most of the n-3 and n-6 PUFAs are metabolized from their precursors, linoleic 
acid (LA; 18:2n-6) and alpha-linolenic acid (ALA; 18:3n-3) respectively. Both LA and 
ALA are metabolized to longer chain PUFAs, largely in the liver, by a series of  
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Fig 1.1 Structure and classification of fatty acids 
 
 
elongation and desaturation reactions to yield longer, more unsaturated fatty acids.  LA is 
converted to AA (20:4n-6) while ALA is converted to eicosapentanic acid (EPA;20:5n-3) 
and docosahexanoic acid (DHA; 22:6n-3). Mammalian organisms, unlike plants do not 
possess the ∆12 and ∆15 desaturase enzymes required for LA and ALA synthesis. 
Therefore these two PUFAs are considered as essential and must be supplemented in the 
diet in order to maintain adequate body pools (Simopoulos, 1999).  
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1.1.3 Dietary sources of PUFAs 
 ALA is the major fatty acid in chloroplast lipids, and hence is the major n-3 
PUFA from plant derived sources. Soybean, canola, perilla, linseed, and rapeseed oils are 
rich sources of ALA, apart from green leafy plants. DHA and EPA are found exclusively 
in aquatic animals as they are synthesized by phytoplankton and algae, which is then 
consumed by fish, mollusks and crustaceans, and thereby concentrated in the aquatic food 
chain (Nettleton, 1995). The relative amounts of DHA and EPA contained in fish oils 
vary considerably between species, with deep sea fish containing more of these n-3 
PUFAs compared to the freshwater ones (Childs et al., 1990). Among the n-6 PUFAs, LA 
can be found in high proportions in many vegetable seeds and oils (safflower, soybean, 
coconut, corn and sunflower). Dietary LA is considered to be the major source of tissue 
AA, although lean meats and meat fat are the direct sources in the human diet (Li et al., 
1998).  
 
1.1.4 Intestinal absorption and metabolism  
 Absorption of dietary n-3 PUFAs depends on the form in which they are ingested. 
Fish and fish oil products are mostly ingested as triglycerides. In mammals, the relative 
absorption of different forms of PUFAs varies as Free PUFA > triglyceride > ethyl ester 
(Nelson and Ackman, 1988). Ingestion of n-3 PUFAs leads to their distribution to 
virtually every cell in the body. The non-esterified fatty acids enter the cells via fatty acid 
transporters and are rapidly converted to fatty acyl-CoA thioesters (FA-CoA) by acyl-
CoA synthetases. A major fraction of these lipids is bound to specific proteins, i.e. fatty 
acid binding protein and FA-CoA-binding protein. FA-CoAs are substrates for neutral 
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lipid (triglycerides, cholesterol esters) and polar lipid (phospholipids, sphingolipids and 
plasmalogens) synthesis (Jump, 2002). On exogenous supplementation, the phospholipid 
pool comprising of phosphatidylcholine and phosphatidylethanolamine, is the major site 
of PUFA incorporation in both cultured normal and transformed cells (de Bravo et al., 
1991).  
 
1.1.5 Function of PUFAs 
 Dietary PUFAs have effects on diverse physiological processes impacting normal 
health and chronic disease, such as the regulation of plasma lipid levels (Harris, 1997; 
Mori et al., 2000), cardiovascular (Nilsen and Harris, 2004) and immune function 
(Hwang, 2000). As structural phospholipids of cell membranes, they modulate membrane 
fluidity, cellular signaling and cellular interaction. Moreover they play an important role 
in the regulation of the immune system by acting as precursors for the synthesis of 
eicosanoids. Arachidonic acid (AA) or EPA are mobilized from the cell membrane by the 
action of the phospholipase enzymes especially phospholipase A2 (PLA2) and C (PLC), 
and subsequently metabolized by cyclooxygenase (COX) and lipoxygenase (LOX) into 
prostaglandins (PGs), thromboxanes (TXs) and leukotrienes (LTs). As membrane 
phospholipids normally contain much higher levels of arachidonic acid (AA) than of the 
other 20-carbon PUFAs (Yaqoob et al., 2000), AA is the most common eicosanoid 
precursor and gives rise to 2-series PGs and TXs and 4-series LTs. In contrast, EPA gives 
rise to 3-series PGs and TXs and 5-series LTs, the difference being the presence of the 
double bond in the structure (Johnson et al., 1983). n-3 PUFAs also play a role in the 
regulation of gene expression (Jump and Clarke, 1999; Duplus et al., 2000). However 
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cell-specific lipid metabolism as well as the regulation of fatty acid regulated 
transcription factors are likely to play an important role in determining how cells respond 
to changes in PUFA composition. 
 
1.1.6 Competition between n-3 and n-6 PUFAs   
 There is competition between n-3 and n-6 PUFAs for their metabolic conversion 
via the desaturase and elongase enzymes, which are common to both pathways. However 
these enzymes have a greater affinity for n-3 PUFAs such that when dietary n-3 intake is 
high, they are preferentially metabolized (Jump, 2002). This leads to competitive 
inhibition of n-6 PUFA metabolism, where linoleic acid desaturation and AA 
concentration are significantly decreased after EPA or DHA supplementation, and 
resulting in decreased generation of AA-derived eicosanoids (Yaqoob et al., 2000; 
Caughey et al., 1996; Thies et al., 2001).  
 
1.2 PUFAs in colon cancer 
1.2.1 Epidemiological studies 
 Fat has been the focus of dietary studies on colorectal cancer more than any other 
component. The initial insight into the relationship between dietary fat and cancer came 
partly from epidemiological studies. With a few exceptions (Macquart-Moulin et al., 
1986; Tuyns et al., 1987), early case control studies showed a positive association 
between the risk of colorectal cancer and the intake of fat and meat (Potter and 
McMichael, 1986; Benito et al., 1990; Graham et al., 1988; Lee et al., 1989; La Vecchia 
et al., 1988). Studies examining the effect of the degree of saturation of fats highlighted 
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saturated fat consumption, as an agent responsible for colorectal cancer (Burnstein, 1993; 
Woutersen et al., 1999). On the other hand, a decrease in risk of colon cancer was 
reported with an increase in the degree of unsaturation of fats (Lee et al., 1989; 
Macquart-Moulin et al., 1987; Benito et al., 1991). 
 A reportedly lower incidence of thrombotic and immunologically mediated 
diseases in Greenland Eskimos when compared with mainland Danish population, 
aroused interest in the potential beneficial effects of marine lipiods (Bjerregaard and 
Dyerberg, 1988). Lanier et al, (1976) in a 5-year survey from 1969-73 observed an 
increase in cancer incidence of lung, colon and rectum among the Alaska Eskimos and 
Aleuts. A further survey of cancer incidence for the years 1989-1993 found that there 
were significant increases in the rates for cancers of prostate and colon in men (Lanier et 
al, 1996). The diet of Eskimos of Alaska is high in fat but this comes largely from marine 
animals and fish (Nobmann et al, 1992). Urbanization of the native population and the 
decreasing trend of fish intake were suggested as contributing factors to the increase in 
cancer rates, implying that fish and fish oils may have a protective risk modifying effect 
in colorectal cancer. In an analysis involving 24 European countries, an inverse 
correlation was found in males between colorectal cancer mortality and current fish 
intake. There was evidence of a protective effect of a high fish intake relative to that of 
dietary sources of n-6 PUFAs (Caygill and Hill, 1995). In a follow-up study, mortality 
from colon cancer correlated with the consumption of animal fat and an inverse 
correlation was observed with fish and fish oil consumption when expressed as a 
proportion of total fat (Caygill et al., 1996). Fish and fish oil being rich sources of n-3 
PUFAs, the findings of this analysis implied that lower levels of n-3 PUFAs and higher 
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levels of n-6 fatty acids in the body may be a predisposing factor in the causation of 
colon cancer.  
 Prospective cohort studies also have shown positive association between fat, meat 
and colorectal cancer. Willett et al, (1990) reported an almost 2-fold higher risk of 
colorectal cancer among women in the highest quintile of red meat consumption in the 
Nurses’ study. The Health Professionals Follow-Up Study, a cohort study of men, also 
demonstrated a direct association between red meat consumption and risk of colon 
cancer, but no association was observed with other sources of fat (Giovannucci et al., 
1994). The protective effects of fish consumption are seen only in areas where fish 
consumption is high. Fishermen on the west coast of South Africa, having a significantly 
higher (110 versus 30g/day) had six times lower colorectal cancer incidence than in white 
urban dwellers (Schloss et al., 1997). In a study in Norway, intake of fish in general had 
no protective effect against colorectal cancer, but the relative risk of people who ate five 
or more fish meals per week was lower than that of people who ate fish less frequently 
(Gaard et al., 1996). Taken together, these results indicate that various types of fat may 
have opposite effects on the risk for colorectal cancer, with meat rich in n-6 PUFAs 
promoting cancer and fish rich in n-3 PUFAs being protective. 
 
1.2.2 Animal studies 
 The second line of evidence in understanding the influence of dietary fat on 
colorectal cancer development came from rodent models. Laboratory animal studies 
provided the evidence that not only the amount of fat but also the types of fat are 
important factors in colon cancer development. Experiments with diets containing 
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saturated fatty acids, n-3 PUFA and n-6 PUFAs clearly show that n-3 PUFA rich diets 
inhibit carcinogenesis (Nelson and Ackman, 1988; Reddy and Maruyama, 1986a; Reddy 
and Sugie, 1988) whereas saturated fats and n-6 PUFA rich diets enhance tumor 
production (Reddy and Maeura, 1984; Reddy and Maruyama, 1986b). In addition, the 
stage of carcinogenesis at which the effect of dietary fat is exerted appears to depend on 
the fatty acid composition, with the n-3 PUFAs being protective in both the initiation and 
promotion phase of carcinogenesis (Reddy and Maruyama, 1986b; Reddy et al., 1991). 
The effects of different n-3 and n-6 fatty acid ratios in experimental colon carcinogenesis 
were studied by Deschner et al, (1990). The highest ratio of n-3:n-6 PUFAs inhibited 
epithelial cell proliferation and induced S-phase arrest in the colonic cells, whereas the 
lowest ratio of n-3:n-6 PUFAs produced the highest tumor incidence in azoxymethane 
treated rats. 
 Germ line mutations of the murine Apc gene provide a model for human familial 
adenomatous polyposis. The inhibitory effect of DHA and DHA-enriched fish oil were 
also demonstrated in mouse models with a mutation at the Apc gene at codon 716 and 
codon 850 respectively (Oshima et al., 1995; Paulsen et al., 1997). The administration of 
DHA has also been shown to inhibit colon cancer cell metastasis with a reduction in the 
matrix metalloproteinase activity (Suzuki et al., 1997; Iigo et al., 1997). These studies 
tend to confirm the epidemiological evidence that n-3 PUFAs are protective, whereas n-6 





1.2.3 Intervention studies in humans 
 Studies describing direct intervention with n-3 PUFAs in human subjects are not 
many. The relative long periods of fatty acid supplementation makes the dietary 
intervention studies difficult to conduct. Subjects, at high risk for colorectal cancer, 
receiving fish oil supplementation showed changes in proliferation pattern of the rectal 
mucosa similar to that observed in the low risk population (Anti et al., 1992; Bartoli et 
al., 1993). In another study, patients with stage 1 or 2 colon carcinoma or adenomatous 
polyps did not develop additional polyps after 12 months of n-3 PUFA supplementation 
(Huang et al., 1996). In contrast, Akedo et al, (1998) reported that Familial Adenomatous 
Polyposis (FAP) patients supplemented with DHA-enriched fish oil capsules, still 
progressed to malignant lesions after 12 months. Though clinical intervention studies are 
more relevant to the human in vivo situation, the existing data are not substantial. More 
studies are needed to confirm the efficacy of clinical application of DHA in colon cancer. 
 
1.2.4 In vitro studies 
 Compared to the numerous epidemiological and in vivo studies that have been 
conducted on colon cancer to determine the role of fatty acids, few studies have tried to 
look into the effect of PUFAs on colon cancer cell lines.(Tsai et al., 1998) showed that n-
3 PUFAs, DHA and EPA inhibited the proliferation of sigmoid colon cancer 
transformants while having little effect on normal cells. In HCT-116 cells transfected 
with inducible COX-2, both DHA and EPA inhibited cell proliferation, compared with 
linoleic acid (Boudreau et al., 2001). In CaCo-2 cells, irrespective of the n-3/n-6 status, 
the longer chain PUFAs - DHA, EPA and AA were more potent in inhibiting growth than 
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α-linolenic acid and linoleic acid (Dommels et al., 2003; Nano et al., 2003). In HCA-7 
cell line, DHA acts synergistically with the selective COX-2 inhibitor, celecoxib, to 
inhibit cyclooxygenase-2 and cell proliferation (Swamy et al., 2004).  In HT-29 cells 
DHA has been shown to inhibit growth and induce cell cycle arrest (Chen and Istfan, 
2001), but the molecular mechanism of these actions still remain to be elucidated. 
 Apart from its effect on cellular proliferation, DHA also modulates other 
functions in colon cells.  In young adult mouse colonic cells DHA, compared with 
linoleic acid inhibited Ras localization to the plasma membrane and GTP binding (Collett 
et al., 2001). Both n-3 and n-6 PUFAs increased the gap junctional intercellular 
communication during spontaneous differentiation of Caco-2 (Dommels et al., 2002). 
DHA increases the metabolism of all-trans-retinoic acid and CYP26 gene expression in 
intestinal cells (Lampen et al., 2001) and selectively activates RXRalpha relative to n-6 
PUFA in colonocytes (Fan et al., 2003). cDNA microarray analysis showed that in CaCo-
2 colon cancer cells, DHA down-regulated the inducible nitric oxide synthase, the 
prostaglandin family of genes, as well as cyclooxygenase-2 expression and several cell 
cycle-related genes, whereas it up-regulated genes associated with apoptosis (Narayanan 
et al., 2003). 
 
1.3 Apoptosis  
 
1.3.1 Apoptosis – A Brief Introduction 
 Apoptosis or programmed cell death is a critical component of both normal 
development and disease (Hengartner, 2000). First described by (Kerr et al., 1972), this 
distinct type of cell death is characterized by cytoplasm swelling, blebbing of the plasma 
membrane, chromatin condensation maintenance of organelle integrity, and condensation 
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and fragmentation of DNA, followed by orderly removal through phagocytosis. The 
importance of apoptotic process can be assessed from the fact that the apoptotic 
machinery has been highly conserved throughout evolution, with many similarities 
between phylogenetically divergent groups including invertebrates and humans (Wyllie 
et al., 1999). Defects in the apoptotic process can result in many pathological conditions 
including cancer, Alzheimer’s disease, stroke and Acquired Immuno-deficiency 
Syndrome (Webb et al., 1997). 
 One of the main executioners of the apoptotic pathway are the caspases. Caspases 
are cysteine-specific proteases that are expressed as inactive precursors. Caspases are 
activated early in the apoptotic cascade either by (i) processing by an upstream caspase 
(ii) ligand binding to the death receptors  (iii) or association with a regulatory subunit like 
Apaf-1 (Hengartner, 2000). The initial activation of caspases is amplified by the caspase 
cascade which also integrates the pro-apoptotic signals. Proteolytic cleavage of cellular 
substrates by caspases largely determines the features of apoptosis. The caspase 
substrates range from the single polypeptide chain enzymes, like polyADP-ribose 
polymerase, to complex macromolecular structures like the lamin network (Creagh et al., 
2003). 
 Mitochondria not only serve as the major energy source in the living cells, but 
they can also trigger or amplify the signals that lead to apoptosis (Green and Reed, 1998). 
Alteration in mitochondrial membrane potential and permeabilisation of the 
mitochondrial membrane often precede caspase activation and other manifestations of 
apoptosis (Zamzami and Kroemer, 2001). Induction of permeability transition in the 
inner mitochondrial membrane may be accompanied by the release of cytochrome c, 
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Smac/Diablo and AIF, leading to the uncoupling of oxidative phosphorylation and 
accelerated ATP hydrolysis by mitochondrial ATPase (Lemasters et al., 2002). The 
mitochondrial pathway is used extensively in response to extracellular signals and 
internal insults such as DNA damage. These diverse response pathways converge on the 
mitochondria, often through the activation of a pro-apoptotic member of the Bcl-2 family. 
The death-receptor pathway and mitochondrial pathways converge at the level of 
caspase-3 activation, which initiates the proteolytic cascade that culminates in apoptosis 
(Green and Reed, 1998). 
 
 
1.3.2 PUFAs and apoptosis 
 
 Both deficiency and excess of PUFAs can influence the extent of apoptosis. The 
reported effects of the n-3 PUFAs, DHA and EPA, on apoptosis have ranged from 
inhibition to stimulation. Apoptotic effects of DHA have been reported in many cancer 
cell lines such as vascular smooth muscle cells (Shiina et al., 1993), Morris hepatic 
carcinoma 3924A (Calviello et al., 1998), mammary carcinoma (Minami and Noguchi, 
1996), and colon cancer cells (Tsai et al., 1998). In contrast, DHA has also been reported 
to exert its protective effect by inhibition of apoptosis. DHA protects neuro2A cells from 
serum deprivation induced apoptosis (Kim et al., 2000) and prevents oxidative stress 
induced apoptosis in retinal cells (Rotstein et al., 2003). In leukemic cells too, DHA 
inhibits sphingosine and TNF/ cyclohexamide-induced apoptosis (Yano et al., 2000; 
Kishida et al., 1998). 
  Among the n-3 PUFAs, DHA and EPA seem to have different effects on 
apoptosis. Administration of low doses of DHA to ACI/T rats transplanted with Morris 
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hepatocarcinoma 3924A resulted in doubling of the number of cells undergoing 
apoptosis, whereas administration of EPA did not affect apoptosis but increased the 
cellular differention (Calviello et al., 1998). For n-6 PUFAs, arachidonic acid and its 
metabolites, and conjugated linoleic acid are also known to induce apoptosis (Bergamo et 
al., 2004; Hawkins et al., 1998). Together these studies indicate that PUFAs induce 
apoptosis in a variety of cell types and the potency to induce apoptosis varies among the 
different PUFAs. 
 
1.4 Oxidative Stress 
1.4.1 Reactive Oxygen Species- Definition and Source   
 Reactive Oxygen Species (ROS) are constantly generated in all organisms as a 
result of aerobic metabolism (Wiseman and Halliwell, 1996). A free radical is any 
species capable of independent existence that contains one or more unpaired electrons 
(Halliwell, 1987). A compound becomes a free radical by either gaining an additional 
electron or by losing one. Oxygen-centred free radicals are the most common because of 
the prevalence of oxygen in the biological system and their high reactivity towards 
various cellular and molecular targets (Halliwell, 1999; Marnett, 2000).  ROS includes 
the hydroxyl radicals (.OH), superoxide anions (O2.-), singlet oxygen (1O2) and hydrogen 
peroxide (H2O2). Among these, .OH, is the most reactive one responsible for most of the 
oxidative damage caused by ROS such as lipid peroxidation and oxidative damage 
(Halliwell, 1999). 
 In aerobic cells, ROS are generated by several pathways. Mitochondria is 
believed to be the major site of ROS production due to the presence of the electron 
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transport chain (Cai and Jones, 1999). During the production of ATP, in the electron 
transport reaction O2 accepts electrons and H+, and gets reduced to water. In the process, 
a small fraction of electrons are leaked to and transferred to O2, thus resulting in the 
formation of O2.- (Kamata and Hirata, 1999). In the mitochondria, ROS formation is 
significantly affected by alterations of mitochondrial lipid composition and by 
lipoperoxidation products (Mates and Sanchez-Jimenez, 2000). Another source of ROS 
production is the endoplasmic reticulum where ROS is generated either by donation of 
electrons from NADPH cytochrome p450 reductase or by the microsomal enzymes 
(hypoxanthine/xanthine oxidase, NADPH oxidase, lipoxygenase, cyclooxygenase) 
(Kamata and Hirata, 1999). 
  
1.4.2 Role of oxidative stress in carcinogenesis and apoptosis 
 Cancer and apoptosis are opposed phenomena but ROS have been widely 
reported to play a key role in both. Low levels of ROS regulate cellular signaling and 
play an important role in normal cellular proliferation (Kamata and Hirata, 1999). 
Interestingly, tumor cells are known to contain elevated levels of ROS (Burdon, 1995). 
Persistent oxidative stress results in accumulation of oxidative damage to several critical 
biomolecules. This eventually results in several biological effects ranging from 
alterations in signal transduction, and activation of transcription factors NF-kB and AP-1 
(Gupta et al., 1999). Oxidative stress can also induce DNA damage, which leads to 
genomic instability and may thus contribute to cancer progression (Jackson and Loeb, 
2001). Compelling evidence for the carcinogenic potential of ROS is the finding that 
ROS is produced in cells stimulated with growth factors such as EGF and PDGF (Bae et 
al., 2000; Bae et al., 1997). Recently it was shown that overexpression of Mox1 (the 
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catalytic subunit of NADPH oxidase) induces superoxide generation. This enzyme has 
been shown to transform NIH3T3 cells and also produce aggressive tumors in athymic 
mice (Suh et al., 1999), illustrating the critical role of ROS in vitro and in vivo. Thus 
ROS are thought to play multiple roles in tumor initiation, progression and maintenance. 
 In contrast to their role in promoting cell growth under non-stress conditions, 
ROS appears to activate and modulate apoptosis when cells are under stress. ROS levels 
are increased in cells exposed to various stress agents, including anticancer drugs (Jabs, 
1999), and they promote apoptosis by stimulating various pro-apoptotic signaling 
molecules, such as ASK1, JNK and p38 (Benhar et al., 2001; Davis, 2000). ROS also 
plays a pivotal role in p53 induced apoptosis (Polyak et al., 1997). In addition ROS can 
act directly on the apoptotic machinery, by accelerating mitochondrial depolarization and 
dysfunction during the effector phase of apoptosis (Jabs, 1999). Thus ROS signaling 
serves as a bifunctional regulator of cell proliferation. 
 
1.4.3 PUFAs and oxidative stress 
 Recent independent observations in diverse models show that PUFAs may act as 
pro-oxidants and suggest an important role for oxidative mechanisms in their effects in 
biological systems.  
 
1.4.3.1 PUFAs and lipid peroxidation 
 Lipid peroxidation is thought to be one of the major mechanisms of PUFA action. 
It is hypothesized that the presence of double bonds makes the PUFAs extremely 
sensitive to oxidation. Membrane phospholipids are pro-oxidised at the allylic position 
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between double bonds of unsaturated free fatty acids, resulting in the generation of lipid 
peroxides (Girotti, 1998). Lipid peroxidation begins with the removal of a hydrogen atom 
from a PUFA double bond, forming a lipid radical. This lipid radical is extremely 
reactive and reacts with molecular oxygen to form a lipid peroxy radical which, in turn, 
attacks another PUFA and propagates further reactions (Rice-Evans and Burdon, 1993). 
Thus a single initiation event results in a chain reaction. The oxidative modification of 
fatty acids results in changes in membrane fluidity, inactivation of membrane bound 
receptors and enzymes, which may lead to impairment of membrane function and cell 
death. In addition, the lipid peroxides can also be mutagenic and genotoxic by causing 
damage to DNA and other macromolecules (Leuratti et al., 2002; Marnett, 2000). 
  
1.4.3.2 PUFAs and Reactive Oxygen Species 
 Another means of PUFA induced oxidative stress is through the production of 
oxidizing agents such as hydrogen peroxide (Madhavi et al., 1994; Sagar et al., 1992). 
PUFA can be metabolized by fatty acyl-CoA oxidase, an enzyme in the β-oxidation 
pathway. In mitochondria, these fatty acid metabolites supply reducing equivalents to the 
redox reactions at complexes I and II. Cells overexpressing acyl-CoA oxidase showed 
that PUFA treatment produced hydrogen peroxide which was accompanied by a decrease 
in cellular proliferation (Okamoto et al., 1997). Apart from peroxides, superoxide anion 
and hydroxyl radical, have also in some instances been associated with the action of 
PUFAs (Anel et al., 1992; Kumar and Das, 1995). On the other hand, fatty acids are mild 
uncouplers that act through a protonophoric effect or through activation of uncoupling 
proteins (UCP) or/ and  of the adenine nucleotide translocase (Wojtczak and Schonfeld, 
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1993; Hermesh et al., 1998) and may reduce mitochondrial hydrogen peroxide generation 
(Korshunov et al., 1998). Fatty acids can also contribute to the cellular antioxidant 
defences against mitochondrial oxidative stress by activating glutathione peroxidase 
through an EGFR-dependent function (Duval et al., 2002). Thus, in the cellular system 
fatty acids may deal with oxidative stress in different ways. 
 
1.5 Mitogen Activated Protein Kinases  
1.5.1 Mitogen Activated Protein Kinase (MAPK) signaling pathways: Introduction 
 Mitogen Activated Protein Kinases (MAPKs) constitute an important group of 
signaling mediators. Signal transduction via MAPKs plays a key role in a variety of 
cellular responses including growth factor-proliferation, differentiation and cell death 
(Cano and Mahadevan, 1995; Robinson and Cobb, 1997). Three major subfamilies of 
structurally related MAPKs have been identified in mammalian cells. These are the 
extracellular signal regulated kinases (ERKs), the c-Jun N-terminal kinases/ stress 
activated protein kinases (JNK/SAPKs), and the p38 kinases. MAPK subfamilies 
phosphorylate their substrates at serine and threonine residues located adjacent to a 
proline residue, and their substrates include diverse cellular molecules, including protein 
kinases and transcription factors (Robinson and Cobb, 1997; Cano and Mahadevan, 
1995). Members of all three MAPK subfamilies are activated by upstream kinases 
(MAPK Kinases, or MKKs) by dual phosphorylation of threonine and tyrosine residues. 
 ERKs are characteristically activated by mitogenic stimuli such as growth factors, 
and are associated with cell proliferation, differentiation and protection from apoptosis. 
In contrast, the JNK and p38 pathways are strongly activated in response to stress stimuli 
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such as UV irradiation, hydrogen peroxide, DNA damage, heat and osmotic shock, and 
are involved in growth arrest and the induction of apoptosis (Kyriakis et al., 1994; 
Raingeaud et al., 1995; Minden and Karin, 1997). The specificity of activating stimuli for 
these three subfamilies of MAPKs is not absolute, and much of the overlapping in their 
roles could be due to different roles of each pathway in various cell types responding to 
different stimuli. 
 
1.5.2 MAPKs and ROS 
 Recent emerging evidence seems to indicate that redox regulation  is important in 
MAPK activation under stress (Adler et al., 1999). It has been demonstrated that ROS 
functions as an intermediate in MAPK activation in response to stress agents such as 
ceramide and anti-cancer drugs (Mansat-de Mas et al., 1999; Shiah et al., 1999). ROS-
dependant MAPK activation has also been implicated in regulating the behaviour of 
tumor cells. Activation of MAPKs in transformed murine cells was shown to be 
independent of the oncogenic transformation but dependant on ROS production (Benhar 
et al., 2001). In human tumor cells also, higher ROS levels and subsequent MAPK 
activity increase the sensitivity to anti-cancer drugs (Benhar et al., 2001). Recently, 
Sakon et al., (2003) and Chen et al., (2003) demonstrated that increased accumulation of 
ROS prolonged the activation of JNK when NF-κB is inhibited. This may be due to either 
the decreased expression of the antioxidant enzymes or the increased expression of the 
p450 genes. In another case, overexpression of manganese superoxide dismutase 
(MnSOD), reduced the oxidative stress and suppressed the JNK/AP-1 pathway in a 
multistage skin carcinogenesis model (Zhao et al., 2001). 
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 The mechanisms, which underlie the ROS-mediated MAPK activation, may 
involve direct alteration of kinases and transcription factors, and indirect modulation of 
cysteine-rich redox-sensitive proteins such as thioredoxin and glutathione S-transferase. 
ASK1, an upstream regulator of MAPK, is inhibited in non-stressed cells through its 
association with thioredoxin (Saitoh et al., 1998). Increased ROS levels lead to 
dissociation of this complex and thereby enable the activation of ASK1 and downstream 
MAPKs (Liu et al., 2000). In the case of JNK, ROS triggers the detachment of JNK 
associated Glutathione-S-transferase-π (GSTp) and thereby facilitating JNK activation 
(Adler et al., 1999). ROS-dependent activation of JNK may also involve the 
downregulation of a JNK phosphatase (Chen et al., 2001). However, apart from these, 
additional mechanisms linking ROS and MAPKs may also exist. 
 
1.5.3 PUFAs and MAPKs 
 Studies looking into relationship of PUFAs and MAPK are not many. In rat liver 
epithelial WB cells and Jurkat T cells, activation of MAPK by PUFA appears to be a 
general response, as both the n-3 and n-6 PUFAs activated MAPKs (Hii et al., 1995; Hii 
et al., 1998). In contrast, in Mesangial cells the activation was selective as only DHA but 
not EPA activated JNK (Yusufi et al., 2003a). Among the n-6 PUFAs, arachidonic acid 
has also been reported to activate JNK but the activation seems to be cell specific. 
Arachidonic acid activates JNK in stromal and rabbit proximal tubular epithelial cells and 
Jurkat T cells, but not in neutrophils (Hii et al., 1998). The cell specific effects of 
arachidonic acid are also seen in haematopoietic cells as arachidonic acid activates JNK 
and p38 in H7.bcr-abl A54, Jurkat and RPMI 7666 cells but not in U937 cells (Rizzo et 
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al., 2002). In contrast, PUFAs are also reported to have an inhibitory effect on MAPK 
activation, as in Jurkat T cells, DHA and EPA inhibited Phorbol Myristate Acetate 
(PMA)-stimulated ERK activation via Protein Kinase C-dependent and –independent 
pathways (Denys et al., 2002; Denys et al., 2001). This indicates that some of the actions 
of PUFA could be mediated via the MAPK cascade.  
 
1.6 Peroxisome Proliferator-Activated Receptors (PPARs) 
1.6.1 Functions of PPARs 
 The peroxisome proliferator-activated receptors (PPARs) are a subgroup of 
ligand-activated nuclear receptors responsible for the regulation of cellular events ranging 
from lipid homeostasis to cell differentiation and apoptosis (Rosen and Spiegelman, 
2001). There are 3 known subtypes of PPARs – PPARα, PPAR β/δ and PPARγ. PPARα 
is mostly present in the liver, kidney, heart and muscle and is involved in the catabolism 
of fatty acids (Braissant et al., 1996). PPAR β/δ is the most widely distributed subtype 
and plays a role in placentation and adiposity (Barak et al., 2002). The most widely 
studied form is PPARγ, which is widely expressed in a variety of cell types, including 
adipocytes, macrophages and colonocytes, and plays a critical role in regulating 
adipocyte differntiation (Willson et al., 2001) 
 The three PPAR isoforms (α,δ,γ) differ in their C-terminal ligand binding 
domains, and each appears to bind and respond to a specific subset of agents including 
hypolipidemic drugs, long chain fatty acids, prostaglandins, and antidiabetic 
thiazolidinediones. Upon ligand binding, the receptor becomes activated and an active 
heterodimer of PPAR and the retinoid X receptor bind to DNA (Murphy and Holder, 
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2000). Binding of the complex to gene regulatory sites on the DNA, termed ‘Peroxisome 
proliferators Response Elements’ (PPRE) leads to increased transcription of numerous 
genes. Target genes induced  include those involved in growth regulatory pathways, lipid 
transport and storage and also in colon cell maturation and immune modulation (Willson 
et al., 2001; Gupta et al., 2001). 
 
1.6.2 PPARγ and colon cancer 
 Studies of humans, animals and cultured cells support the view that modulation of 
PPARγ activation may have therapeutic benefits (Murphy and Holder, 2000; Sporn et al., 
2001; Gupta and DuBois, 2002). Apart from adipocytes, PPARγ is abundantly expressed 
in the colon (Fajas et al., 1997) with the highest level of receptor expression observed in 
postmitotic, differentiated epithelial cells facing the lumen (Lefebvre et al., 1999). 
Consistent with this expression pattern, mutations of PPARγ have been reported in colon 
cancers (Kinzler and Vogelstein, 1996). Each of the cancers with the mutant PPARγ also 
had a normal PPARγ allele. This suggests that even a partial loss of PPARγ function 
enhances the transformation to colon cancer. Human colon cancer cell lines with a point 
mutation in the PPARγ gene fail to undergo differentiation or growth inhibition even in 
the presence of agonists (Gupta et al., 2003).  But still, the role of PPARγ in colon cancer 
is controversial, as both the suppression and enhancement of tumor growth have been 
observed in different animal models treated with activators of PPARγ. In nude mice, 
treatment with PPARγ ligands resulted in a reversal of events associated with colon 
cancer, and yielded smaller tumors (Sarraf et al., 1998). But in contrast, in a Min+/- mice 
model, which lacks one functional copy of the APC tumor suppressor gene thus 
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predisposing them to cancer, treatment with PPARγ ligands, troglitazone and 
rosiglitazone- resulted in an increased number of tumors (Lefebvre et al., 1998; Saez et 
al., 1998) These conflicting results have been partially explained by the demonstration 
that in mice with mutated APC gene, PPARγ loses the ability to regulate colon 
tumorigenesis, whereas in wild type APC mice, PPARγ functions as a tumor suppressor 
gene (Girnun et al., 2002). This is relevant in human cancers because mutation of the 
APC gene is often the initiating event for the majority of sporadic colorectal tumors 
(Powell et al., 1992). Clearly, additional studies are required to determine the role of 
ligands of PPARγ in both the prevention and treatment of colon cancer. 
 
1.6.3 PUFAs and PPARs  
  Fatty acids have been shown to bind and to activate PPARs (Desvergne and 
Wahli, 1999). The fatty acids bind all the three PPARs, with PPARα exhibiting the 
greatest affinity. Compared with the saturated and monounsaturated fatty acids, PUFAs 
generally have a higher affinity for the receptors (Kliewer et al., 1997). Among the 
PUFAs, DHA can preferentially activate PPARγ more than LA. As for PPARα, and –δ, 
the activation was comparable (Yu et al., 1995). That PUFAs act as activators of PPARs 
has led many to view PPARγ as the link between dietary fat and colorectal cancer 
(Willson et al., 2001). It has been proposed that the increase in colonic polyps seen with 
the PPARγ ligand treatment is consistent with the increase in polyp burden observed 
when these mice were placed on a high-fat diet (Lefebvre et al., 1998; Saez et al., 1998). 
However there were significant differences between the two types of treatment. PPARγ 
ligands induced polyps only in the large intestine compared to the high-fat diet which 
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increased the polyp number in both the small and large intestines, suggesting that fatty 
acids may activate other pathways also in addition to PPARγ activation. That fatty acids 
can also act as hormones that control the activity of transcription factors proves that fatty 
acids are not merely energy providing molecules but are also metabolic regulators. This 
finding opens novel perspectives for the in depth understanding of the therapeutic role of 
fatty acids. 
 
1.7 Objectives of the study 
 Evidence from epidemiological studies and animal models suggest that n-3 
PUFAs have a protective effect on colon cancer. But the mechanisms of the 
chemotherapeutic and chemopreventive actions of n-3 PUFAs are still unknown. DHA, 
abundantly found in fish oil, is one the principal n-3 PUFAs. The aim of this study is to 
explore the molecular mechanisms of the effects of n-3 fatty acids, and DHA in 
particular, in colon cancer cell lines. The specific aims are summarized as follows: 
(1) To look into the effects of saturated, monounsaturated, and n-3 and n-6 
polyunsaturated fatty acids on cell proliferation and viability of colon cancer cell 
lines. 
(2)  To study the apoptotic effects of the n-3 PUFA, DHA in the colon cancer cell line, 
HT-29. 
(3)  To elucidate the effect of the MAPK signaling pathways in DHA-induced apoptosis 
in colon cancer. 
(4) To study the role of oxidative stress in activation of MAPKs and induction of 
apoptosis by DHA. 











MATERIALS AND METHODS 
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2.1 Cell lines and chemicals 
 
 Human colon cancer cell lines HT-29, HCT-116, SW480 and Colo205 were 
purchased from American Type Culture Collection (ATCC, Rockville, USA). All fatty 
acids, culture media (McCoy 5A, DMEM, RPMI1640), fatty acid free-bovine serum 
albumin, Triacsin C, etomoxir, ciglitazone, BADGE, and human recombinant TNF-α  
were from Sigma (St Louis, MO). Antibodies against PARP, caspase-3, c-jun, phospho-c-
jun (Ser 63), p38 MAPK, phospho-p38 MAPK, p44/42 MAPK and phospho-p44/42 
MAPK were from Cell Signaling (Beverly, MA). Antibodies against JNK1, COX-2, 
PPARγ and tubulin were from Santa Cruz (Santa Cruz, CA). The secondary antibodies 
(horseradish peroxidase conjugated goat anti-mouse and goat anti-rabbit IgG) and the 
enhanced chemiluminescence (ECL) substrate were from Pierce (Rockford, IL). The 
Caspase-3/7 Assay Kit was purchased from Promega (Madison, USA). The pan-caspase 
inhibitor z-VAD-fmk, JNK inhibitor SP600125; the p38 inhibitor SB203580, and the 
p44/42 inhibitor PD98059 were purchased form Calbiochem (San Diego, CA). 2’7’-
dichlorofluorescein diacetate (DCFH-DA) was purchased from Molecular Probes, Inc 
(Eugene, OR, USA). pNF-κB-luc vector (Mercury Pathway Profiling System) was from 
Clontech (San Diego, CA). Research Biolabs synthesized PPARγ sense and antisense 
oligonucleotides. Luciferase assay kit was from Promega (Madison, WI). Lipofectamine 
transfection reagent was from Invitrogen (Carlsbad, CA). Radioactive probe γ-P-32 was 
from Perkin-Elmer (Shelton, CT). The pDsRed expression vector was obtained from 
Clontech (Palo Alto, CA). The dominant negative JNK1 and JNK2 vectors (DN-JNK1, 




2.2 Cell culture and fatty acid supplementation 
HT-29 and HCT-116 cells were cultured in McCoy 5A; SW480 in DMEM; and 
Colo205 in RPMI 1640 medium supplemented with 10% FBS and 100 units/ml penicillin 
and 100 µg/ml streptomycin. All cells were incubated in a humidified atmosphere of 5% 
CO2 at 37o C. In all experimental procedures, cells were serum starved for 12 hours 
before chemical treatment. Fresh serum free medium was then added for various 
designated treatments.  
For fatty acid supplementation, all fatty acids were dissolved in absolute ethanol. 
In order to minimize the oxidation of fatty acids, stock solutions (50 mM) were stored 
under nitrogen at -80oC. The necessary aliquot of the stock solution was combined with 
fatty acid free-bovine serum albumin (BSA) at a molar ratio of 1:1 in serum free medium. 
In all experiments, the control group was supplemented with the same concentration of 
fatty acid free-BSA in ethanol. The fatty acid-albumin complex solution was freshly 
prepared and filtered before use. All aliquots of fatty acids were used within a week.  
 
2.3 Determination of cell viability – MTT assay  
Tetrazolium dye- 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide 
(MTT) colorimetric test was used to monitor cell growth indirectly as indicated by the 
conversion of the tetrazolium salt to the colored product, formazan, the concentration of 
which was measured spectrophotometrically (Hansen et al., 1989). Cells were seeded in 
96-well microplates at a density of 1x104 cells/well in100µl medium. After incubation 
with PUFAs in serum-free medium for the indicated time periods, 25 µl of MTT solution 
(5 mg/ml) was added to each well. After 2 hours, 100 µl of lysis buffer (50% DMF and 
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20% SDS, pH 4.6) was added into each well and further incubated for another 2 hours. 
The plate was then read using a microplate reader (BIORAD model) at a wavelength of 
595 nm. The absorbance was proportional to the survival of the cells. 
 
2.4 Evaluation of cell morphological alterations 
 
Cell morphological alterations were evaluated by two ways: (i) Cell 
morphological conditions were examined under an inverted microscope (Nikon 
TE2000S). The morphological criteria for apoptosis included cytoplasmic and nuclear 
shrinkage, chromatin condensation and cytoplasmic blebbing. (ii) Nuclear condensation 
was assessed by 4’, 6-diamidino-2-phenylindole (DAPI) staining method. Cells were 
fixed with 70% ethanol and then washed with PBS. DAPI was then added to the fixed 
cells and visualized under a fluorescent microscope using UV. Apoptotic cells were 
identified by condensation and fragmentation of nuclei. 
 
2.5 Determination of sub-G1 population 
DNA fragmentation during apoptosis leads to extensive loss of DNA content, 
which results in a distinct sub-G1 peak when analyzed by fluorescence-activated cell 
sorter (FACS) analysis (Nicoletti et al., 1991). At the end of various treatments, cells 
were scraped and washed twice with PBS. Cells were then resuspended in PBS, fixed and 
permeabilised by 70% ice-cold ethanol for 1 hour. Cells were then incubated with freshly 
prepared PI staining buffer (0.1% TritonX-100, 200 µg/ml RNAse A and 20 µg/ml PI in 
PBS) for 15 minutes at 37oC followed by flow cytometry analysis. 10,000 cells were 
counted and analysed by WinMDI 2.7 software (Scripps Institute, La Jolla, CA). The 
percentage of sub-G1 cells were considered as apoptotic cells. 
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2.6 Measurement of cellular caspase-3 activity. 
Cellular caspase-3 activity was measured by a spectrofluorometric method using a 
commercial Apo-ONE Homogeneous Caspase-3/7 Assay Kit. Cells were plated in 96-
well plates and after the designated treatment, the mix of caspase substrate and 
homogeneous buffer was added. After gentle mixing, the contents were incubated for 2 
hours. The fluorescence was then measured by a spectrofluorometer (Tecan 
SpectrofluorPlus) at an excitation of 485 nm and emission at 530 nm. 
 
2.7 Western Blotting 
 
At the end of various designated treatments, cells were collected, washed twice 
with PBS, and resuspended in 100 µl of ice cold M2 lysis buffer (20 mM Tris-HCl (pH 
7.5),0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 1 M DTT, 0.1 M PMSF, 1 
M β-glycerol phosphate, 0.1 M sodium vanadate and the proteinase inhibitor cocktail). 
Lysates were sonicated for 1 second with a micro-ultrasonic cell disruptor and 
centrifuged at 12,000 x g at 4oC for 15 minutes, and the supernatant was collected. The 
protein concentration was detected using a protein assay kit (BIORAD) and 30-50 µg of 
protein was loaded to 10% SDS gels. After electrophoresis at 120 V for 60 minutes, the 
protein gel was transferred to a nitrocellulose membrane. The membrane was then 
blocked for 1 hour by 5% non-fat milk in TBST buffer (10 mM Tris-HCl (pH 7.5), 100 
mM NaCl, 0.1% Tween). After washing in TBST, the membrane was then incubated with 
the primary antibodies, in 5% non-fat milk, overnight at 40C. After washing with TBST, 
the membrane was then incubated with secondary antibody conjugated with IgG-
horseradish peroxidase (1:5000) for 1 hour at room temperature, followed by washing 
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with TBST. The signal was detected using enhanced ECL systems, captured and analysed 
by the Kodak Image System IS-440CF and Kodak 1D software. 
 
2.8 JNK in vitro kinase assay 
 Cells were grown to confluence in 6-well plates and were serum starved for 12 
hours. Cells were then exposed to various concentrations of DHA for 1 hour. After 
treatment , cells were then lysed with ice cold M2 lysis buffer (20 mM Tris-HCl (pH 
7.0),0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 1 M DTT, 0.1 M PMSF, 1 
M β-glycerol phosphate, 0.1 M sodium vanadate and proteinase inhibitor cocktail) and 
centrifuged at 12000 x g for 15 min at 4oC. To immunoprecipitate JNK, 0.2 µg of anti-
JNK1 antibody was added to cell lysate containing 200 µg of total cellular protein and 
mixed for 2-4 hours at 4 oC.  Recombinant protein A-sepharose beads were then added, 
and the reaction slurry was mixed for 2-4 hours at 4 oC. The immunoprecipitation 
complexes were washed twice with ice cold lysis buffer and then with kinase assay buffer 
(20mM HEPES, pH 7.5, 20 mM β-glycerol phosphate, 10mM MgCl2, 1 M DTT and 0.1 
M sodium vanadate ).The kinase assay reactions consisted of kinase buffer supplemented 
with 20 µM ATP containing 10µCi of [γ-32P]ATP and 1µg of GST-c-jun. The reaction 
was carried out at 30oC for 30 minutes. The reaction was stopped by the addition of 
Laemmli SDS-sample buffer containing β-mercaptoethanol. Samples were boiled for 5 
minutes and then run on 10% SDS-PAGE gels. Kinase activity was measured as the 




2.9 Transient transfections  
 For transfection studies, cells were grown to 60% confluency and were transiently 
transfected by a liposome mediated method using Lipofectamine Plus Reagent 
(Invitrogen), following the manufacturer’s instructions. For JNK studies, cells were 
transfected with either the control vector pcDNA or the dominant-negative (DN) mutants 
of JNK plasmid, pcDNA-DN-JNK1 and pcDNA-DN-JNK2. To inhibit PPARγ protein 
expression, antisense oligonucleotides (5'-CTCTGTGTCAACCATGGTCAT-3') were 
used to inhibit the FLIP initiation codon. Control cells were transfected with sense 
oligodeoxynucleotides (5'-ATGACCATGGTTGACACAGAG-3') (Nikitakis et al., 
2002).  Transfected cells were allowed to grow to confluence prior to use in experiments. 
 
2.10 Luciferase Assay 
 For the luciferase assay, cells were transfected either with 1 µg of pNF-κB-luc 
vector or with 3XPPRE-tk-luciferase vector (with three copies of PPRE upstream of the 
TK promoter/luciferase gene) using Lipofectamine reagent.  For each experiment the 
total amount of transfected DNA per well was kept constant by using the corresponding 
empty vector. The luciferase activity was measured in the cellular extracts using a 
luciferase assay kit. Following treatment, the cell lysate was collected from each well 
after the addition of 1x cell culture lysis reagent (50 µl/well in 24-well plate). The relative 
light units (RLU) were then determined in a luminometer (Lumi-One, Trans Orchid, 




2.11 Measurement of ROS 
 Intracellular ROS generation was measured by the fluorescent probe, 2’7’-
dichlorofluorescein diacetate (DCFH-DA). The method is based on the principle that 
DCFH-DA, a non-fluorescent and non-polar compound, can readily cross the cellular 
membrane to enter the cell. Cleavage of the acetate moiety of DCFH-DA by intracellular 
esterases causes the polar 2’7’-dichlorofluorescein (DCFH) to be trapped inside the cell 
and available for oxidation by peroxides or hydroperoxides to the fluorescent 2’7’-DCF. 
24 hours after seeding, cells were incubated with 10µM DCFH-DA (dissolved in DMSO) 
for 30 min at 37oC. The cells were then washed with PBS twice and treated with different 
agents for 1 hour at 37 oC. After incubation, cells were chilled on ice and were washed 
with ice-cold PBS, scraped from the plate, and resuspended in PBS. The fluorescence 





















EFFECT OF DHA ON VIABILITY OF COLON CANCER CELLS 
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3.1 INTRODUCTION 
Dietary fat plays an important role in colon cancer. Epidemiological and 
experimental studies have shown that different classes of dietary fatty acids have 
different effects on tumor development. In general, n-3 polyunsaturated fatty acids 
(PUFAs), especially DHA and EPA, are reported to be chemopreventive, whereas PUFAs 
of the n-6 variety enhance the development of colon tumors (Roynette et al., 2004; 
Reddy, 1994). However, although the inhibitory effects of n-3 PUFAs on cell 
proliferation have been described, far less information is available with respect to their 
mechanism of action.  
Apoptosis or programmed cell death is defined as the ability of the cells to self-
destruct by activation of intrinsic cellular programs. In different cell lines, DHA has been 
reported to induce apoptosis (Calviello et al., 1998; Minami and Noguchi, 1996; Shiina et 
al., 1993; Tsai et al., 1998), and also inhibit it (Kim et al., 2002; Kishida et al., 1998; 
Rotstein et al., 2003). On the other hand, DHA can also inhibit cell growth by inducing 
cell cycle arrest (Siddiqui et al., 2003; Albino et al., 2000) or cell differentiation 
(Chamras et al., 2002). Though DHA can act by multiple pathways, the cellular and 
molecular mechanisms of its anticancer effect in colon cancer still need to be explored. 
In this study, we aim to investigate the sensitivity of human colon cancer cell 
lines to different fatty acids, and to elucidate the potential mechanism of the 






3.2.1 Cytotoxic effects of PUFAs  
3.2.1.1 Effect of different fatty acids on cell viability of HT-29 cells 
The effect of different fatty acids on the survival of human colon cancer cell line 
HT-29 was determined by MTT assay. As shown in Fig 3.1, a 48 hour exposure to the 
saturated fatty acid – palmitic acid, and the monounsaturated fatty acid – oleic acid, did 
not have any inhibitory effect. Among the polyunsaturated fatty acids, all the PUFAs 
tested had an inhibitory effect, with DHA being the most potent. Although all PUFAs are 
structurally similar and possess unsaturated bonds, the cytotoxic effects of the n-6 
PUFAs, arachidonic acid and linoleic acid, could be seen only at high doses.  
 
3.2.1.2 Effect of DHA on cell viability of different colon cancer cell lines.  
The growth inhibition effect of DHA was further confirmed using three additional 
colon cancer cell lines, SW480, HCT116 and Colo205. Cells were treated with 
50,100,150 and 200 µM DHA for 48 hours and the viability was measured by the MTT 
assay. As shown in Fig 3.2, DHA inhibited the cell viability of all the four cell lines in a 
dose dependent manner. These results suggest that colon cancer cells are highly 
susceptible to the cytotoxic effects of DHA. 
 
3.2.1.3 Effect of metabolic pathway inhibitors on DHA-induced cell death 
To assess whether, DHA must be metabolized to exert its cytotoxic effect, we 
used the general lipoxygenase (LOX) inhibitor, nordihydroguaiaretic acid, NDGA (20 
µM); the acyl-CoA synthetase specific inhibitor, Triacsin C (2 µM); and the 
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mitochondrial β-oxidation inhibitor, etomoxir (50 µM). All the three inhibitors were used 
at subtoxic concentrations. Fig 3.3 shows that acting individually, NDGA, Triacsin C and 
etomoxir did not have any significant effect on cell viability. When 100µM DHA was 
cotreated with either of these compounds for 48 hours, there was no significant effect on 
DHA-induced cell death. This result shows that the free fatty acid form of DHA, and not 
its metabolites, is responsible for its cytotoxic effects. 
 
3.2.2 DHA-induced cell death is apoptotic 
 The hypothesis that DHA induces apoptosis in colon cancer cells was investigated 
by (i) morphological changes of nuclear condensation and fragmentation, visualised by 
DAPI staining (Fig 3.4); (ii) measuring the percentage of sub-G1 cells using fluorescence 
activated cell sorting (FACS) analysis (Fig 3.5) ; and (iii) poly-adenosine-diphosphate-
ribose polymerase (PARP) cleavage, which is cleaved from 113 kDa to 89 and 24 kDa 
fragments (Fig 3.6). 
 HT-29 cells were treated with 0, 50,100 and 200 µM DHA for 48 hours. 
There was a dose-dependent increase in the apoptosis parameters with DHA-treatment. 
The results of the time-course of PARP-cleavage are shown in Fig 3.6(b). HT-29 cells 
were treated with 100 µM DHA for 6, 12, 24 and 48 hours respectively. The cleaved unit 






3.2.3 DHA-induced apoptosis is caspase mediated 
 
3.2.3.1 Determination of caspase-3 activation 
The results to determine whether DHA-induced apoptosis is linked to caspase-3 
activation are shown in Fig 3.7. Panel (a) shows the time course of activation of caspase-
3. A statistically significant increase of caspase activity was seen from 12 hours onwards 
and the activity reached a maximum at 24 hours. This activation of caspase-3 was further 
confirmed by western blotting, as shown in Fig 3.7 (b). Consistent with the above results 
of PARP cleavage, cleavage of procaspase-3 was evident from 12 hours onwards and the 
degree of cleavage increased with time. These results indicate that caspase-3 activation is 
induced by DHA treatment in colon cancer cells. 
 
3.2.3.2 Effect of caspase-3 inhibitor on DHA-induced cell death 
To assess whether caspase activation was necessary for DHA-induced cell death, 
HT-29 cells were preincubated for 1 hour with increasing concentrations (10, 20, 50 µM) 
of z-VAD-fmk, a caspase-3 inhibitor, and then treated with 100 µM DHA for 48 hours. 
Fig 3.8 shows that preincubation with z-VAD-fmk inhibited the cell death induced by 
DHA. As shown earlier in Fig 3.7 (a), z-VAD-fmk blocked the increase of caspase-3 
activity induced by DHA.  This result suggests that caspase-3 activation is essential for 




 Though several studies have reported on the effects of PUFAs on cancer cells, the 




Fig 3.1. Effect of various fatty acids on viability of HT-29 cells. Cells were treated 
with 0–200 µM of Docosahexaenoic acid (DHA), Eicosapentaenoic acid 
(EPA), Arachidonic acid (AA), Linoleic acid (LA), Oleic acid (OA) and 
Palmitic acid (PA) for 48 h. Cell viability was measured by MTT assay. 
Results are the mean of triplicate plates in triplicate assays. Error bars 






























































Fig 3.2 Effect of DHA on viability of colon cancer cell lines. Cells were treated with 
0–200 µM of DHA for 48 h. Cell viability was measured by MTT assay. 
Results are the mean of triplicate plates in triplicate assays. Error bars 













Fig 3.3 Effect of inhibitors of metabolic pathways on DHA induced cytotoxicity. 
Cells were treated with 20 µM NDGA (LOX inhibitor), 2 µM Triacsin C 
(AcylCoA Sunthetase inhibitor) or 50 µM Etomoxir (mitochondrial β-
oxidation inhibitor) in the presence or absence of 100 µM of DHA for 48 h. 
Cell viability was measured by MTT assay. Results are the mean of 


























Fig 3.4 Apoptotic changes induced by DHA . HT-29 cells were treated with 
50,100,200 µM DHA for 48 hours. The nucleus of the cells was stained by 
DAPI and visualized by fluorescence microscopy. The cells with nuclear 
condensation were considered as apoptotic cells.
control DHA 50µM
DHA 100µM DHA 200µM
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Fig. 3.5 Dose response of DHA-induced apoptosis evaluated by measuring sub-G1 cells 
using flow cytometry. Cells were treated with 0 (control), 50, 100, and 200µM 
DHA for 48 hours. The percentage shown in each histogram was the percentage of 
apoptotic cells indicated by sub-G1 cells. The histograms are from one 
representative set of experiment of 3 independent experiments.
control DHA 50µM
DHA 100µM DHA 200µM
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Fig 3.6 (a) Dose-response of the effect of DHA on cleavage of PARP as determined 
by western blot. HT-29 cells were treated with 0, 50, 100 and 200 µM DHA 
for 48 hours.(b) Time-course of PARP cleavage by DHA. Cells were treated 
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Procaspase 3
Cleaved caspase 3
Fig 3.7 Effect of DHA on caspase-3 activation. (a) Time course of DHA-induced 
caspase-3 activation. HT-29 cells were pretreated with or without the z-VAD-
fmk for 1 hour and then treated with 100 µm DHA  for the indicated times. (b) 
Westerm blot showing procaspase-3 cleavage. Data in (a) and (b) are 





























DHA 100uM            - - +                  +                  +       +
z-VAD-fmk(µM)     - 50                 - 10                20               50 
Fig 3.8. Effect of caspase inhibitor on DHA-induced cytotoxicity. HT-29 cells were 
pretreated with or without the z-VAD-fmk for 1 hour and then treated with 100 
µm DHA for 48 hours. Cell viability was measured by MTT assay. Results are 
the mean of triplicate plates in triplicate assays. Error bars represent the 
standard deviations 
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Furthermore, the route of administration of fatty acids may significantly affect 
experimental results. Direct administration of fatty acids to culture medium may reduce 
binding of growth factors to their cognate receptors through a detergent like effect 
(Yusufi et al., 2003). In order to avoid this complication, in our study the fatty acids were 
administered as an albumin–fatty acid complex. As albumin is also important in vivo for 
binding and transporting PUFAs in the blood, the administration of PUFAs with BSA 
simulates the form of PUFA available to cells in vivo. Serum has also been shown to alter 
the susceptibility to PUFAs. With a higher serum concentration, cells have been reported 
to tolerate higher PUFA doses (Begin et al., 1985; Maehle et al., 1995). To minimize the 
influence of serum, the cells were serum starved for 12 hours before each experiment and 
the same protocol was followed for all subsequent experiments. 
In the current study, we used four human colon adenocarcinoma cell lines, HT-29, 
HCT116, SW480 and Colo205 to explore the effects of different fatty acids on cell 
growth and death in vitro. These cell lines differ from each other in many aspects 
including APC, p53, Mismatch repair (MMR) genes and COX-2 status. We showed that 
among all cell lines studied, DHA inhibited cell proliferation more than other n-3 PUFAs 
(EPA) and n-6 PUFAs (AA and LA). The difference in effect of different fatty acids 
cannot be due to the differences in their uptake as it has been shown that in the colon 
cancer cell lines, HT-29 and Caco-2, the individual fatty acids are effectively 
incorporated on supplementation (Awad et al., 1996; Nano et al., 2003). 
Fatty acids enter cells via fatty acid transporters and are rapidly converted to fatty 
acyl-CoA esters by the enzyme acyl-CoA synthetase. The fatty acyl-CoAs are channeled 
to different metabolic pathways such as lipid synthesis, elongation, desaturation, β-
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oxidation and protein acylation reactions (Tomoda et al., 1987). To investigate whether 
the conversion of DHA to its acyl-CoA form was essential for its cytotoxic effect, 
Triacsin C was used to inhibit acyl CoA synthetase. Triacsin C did not have any effect on 
the cytotoxic potential of DHA, indicating that acylation of DHA was not essential for its 
growth inhibitory effects. Excess fatty acids may also lead to increased cycling through 
mitochondrial β-oxidation pathways generating ROS (Kadenbach et al., 2000). Increased 
mitochondrial fatty acid oxidation results in decreased availability of fatty acids for 
triacylglycerol synthesis. This lipid partitioning effect has been shown to affect apoptosis 
in breast cancer and glioma cells lines (Hardy et al., 2003; Berge et al., 2003).However, 
in colon cancer cells, inhibition of carnitine palmitoyltransferase (CPT) I, the rate 
limiting enzyme of fatty acid β-oxidation, by etomoxir did not influence the cytotoxicity 
of DHA. During cellular metabolism, retroconversion of DHA to EPA is possible. EPA 
can exert its action by metabolism via the 5-Lipoxygenase (LOX) pathway to form the 4-
series leukotrienes (LTs). Inhibition of the LOX pathway by NDGA also did not have 
any effect on DHA induced cytotoxicity. Taken together, all these results show that the 
free fatty acid form of DHA, and not its metabolites, is responsible for its cytotoxic 
action in colon cancer cells. 
Induction of programmed cell death in cancer cells is a critical mechanism of 
action of many treatment modalities. We show that cell death induced by DHA is 
apoptotic by demonstrating the cell morphological changes, increase in sub-G1 
population and PARP cleavage. These results are in accordance with previous studies that 
have reported the induction of apoptosis in colon cancer cells by DHA (Chen and Istfan, 
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2000; Narayanan et al., 2001). However the mechanism of DHA induced apoptosis still 
remains unexplained.  
Caspase-3 is an active cell death protease involved in the execution of apoptosis 
and is activated in response to various apoptotic stimuli (Thornberry and Lazebnik, 
1998). However, caspase-independent routes to cell death, involving autophagy and 
proteasomal degradation are also known to occur in apoptotic cells (Lockshin and Zakeri, 
2002). Fatty acids, such as butyrate, have been reported to induce caspase-independent 
apoptosis in some cell lines (Kurita-Ochiai et al., 2003). Our results show that in colon 
cancer cells, DHA caused activation of caspase-3, which was critical in the induction of 
apoptosis, as blockade of caspase activation inhibited the DHA-induced apoptosis (Fig 
2.8). 
In summary, the overall data suggest that DHA induces many of the hallmarks of 
apoptosis in colon cancer cells. The precise mechanisms of how DHA induces apoptosis 












EFFECT OF DHA ON 
REACTIVE OXYGEN SPECIES (ROS) GENERATION AND 




 The mitogen-activated protein kinase (MAPK) family members transduce signals 
from the cell membrane to the nucleus in response to a wide range of stimuli, including 
stress. It has been shown that extracellular signal-regulated kinases (ERKs) are important 
for cell survival, whereas c-Jun N-terminal kinases (JNKs) and p38 MAPKs are deemed 
stress responsive and thus involved in apoptosis (Wada and Penninger, 2004). While 
many reports exist about JNK or p38 MAPK activation in apoptosis induced by various 
stimuli, the role of MAPKs in DHA-induced colon cancer apoptosis has not been 
investigated. ROS has been recognized as an important regulator of stress response in 
many cell types and has also been implicated in MAPK activation (Adler et al., 1999). 
Therefore in the present study, as part of an effort to identify the molecular mechanisms 
underlying DHA-induced apoptosis, we try to answer the questions of whether MAPKs 
are activated by DHA and the significance of oxidative stress in the activation of MAPK 




4.2.1 Effect of DHA on MAPK signaling pathways 
4.2.1.1 DHA induces MAPK activation 
 To explore the role of MAPKs in DHA induced cell death, HT-29 cells were 
serum starved for 12 hours and then treated with DHA. Activation of ERK and p38 
MAPK was detected using antibodies that recognize their phosphorylated (activated) 
forms. Phosphorylation of c-jun was used to assess the activation of JNK. The 
immunoblot of the unphosphorylated forms served as the loading control. Fig 4.1(a) 
shows the time-course of phosphorylation of all the three MAPKs. Activation of JNK 
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started after 30 minutes of DHA exposure. p38 phosphorylation started around 60 min 
and started declining after 2 hrs. However, ERK was activated rapidly at 15 minutes and 
showed a time-dependant increase till 4 hrs. The dose-response of MAPKs to 0-200 µM 
DHA is shown in Fig 4.1(b). Activation of JNK and phosphorylation of c-jun and p38 
were clearly evident upon treatment with DHA concentration of 100 µM and higher. 
ERK however was activated even with 50µM DHA. Protein expression levels of c-jun, 
p38 and ERK were not significantly affected by the treatment, indicating that the increase 
is due to phosphorylation only. 
          To further confirm the activation of JNK by DHA, JNK activity was assessed by 
the in vitro phosphorylation of c-jun, the results of which are shown in Fig 4.2.  
Consistent with the results in Fig 4.1, DHA activated JNK in a time- and dose-dependent 
manner. The kinase assay being more sensitive than immunoblotting, slight activation 
was seen at 15 minutes and reached a maximum at 60 minutes (Fig 4.2a). A dose 
dependent JNK activation was clearly evident with concentrations of 100µM and higher 
(Fig 4.2b).  
 
4.2.1.2 Effect of MAPK inhibitors on DHA-induced cell death 
 To determine if the activation of MAPKs is responsible for mediating the killing 
of HT-29 cells, the effect of specific inhibitors of these pathways on DHA-induced cell 
death was examined. The inhibitors used were SP600125 for JNK, SB203580 for p38 and 
PD98059 for ERK. Cells were pre-treated with the different MAPK inhibitors for 60 
minutes followed by addition of 100 µM DHA and cell viability was measured 48 hours 
later by the MTT assay. The results in Fig 4.3 (a) suggest that the MAPK inhibitors alone 
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did not have any effect on the growth of HT-29 cells. However inhibition of the JNK 
pathway with SP600125 showed a significant protection against the cytotoxicity of DHA. 
Pre-treatment with the p38 inhibitor or ERK inhibitor, did not affect the DHA-induced 
cytotoxicity. The protective effect of SP600125 was further confirmed by assessing the 
PARP cleavage by western blotting. Panel (b) shows that preincubation with SP600125 
inhibited the PARP cleavage induced by DHA, which is consistent with the lower 
percentage of cell death as measured by MTT. Collectively, these results suggest that the 
activation of the JNK pathway mediates DHA-induced apoptosis. 
 
4.2.1.3 Effect of JNK mutants on DHA-induced cell death 
 We further sought to establish the role of JNK in DHA-induced cell death by 
using a transient-transfection death assay. Cells were transiently transfected with 
dominant-negative JNK1 and JNK2 vectors (DN-JNK1 and DN-JNK2) together with 
pDsRed fluorescence protein expression vector as a transfection marker. Cells transfected 
with an empty vector pc-DNA were used as a control. The effectiveness of DN-JNK1 and 
DN-JNK2 transfection was confirmed by significant reduction in c-Jun phosphorylation 
induced by DHA (Fig 4.4a). As shown in Fig 4.4(b), the successfully transfected cells 
were marked by the strong red fluorescence. The survival of transfected cells was 
determined 48 hours after DHA treatment by assessing the morphological changes and by 
DAPI staining. DHA treatment resulted in cell death among most of the cells transfected 
with pc-DNA. In contrast, the ectopic expression of DN-JNK1 and DN-JNK2 markedly 
reduced the extent of cell death caused by DHA. Fig 4.4(c) shows the quantitative 
analysis performed by counting the percentage of cell death among the transfected cells 
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in 10-randomly selected fields. With DHA treatment, the transfected cells showed a 
significantly lower percentage of cell death as compared with cells transfected with the 
empty vector pcDNA. This shows that DHA was unable to exert its cytotoxic action in 
the absence of JNK.  
 
4.2.2 Role of ROS in DHA-induced MAPK activation and cell death 
4.2.2.1 Generation of ROS by DHA 
 In this study, intracellular ROS formation was estimated by DCF fluorescence. 
The time-course changes of ROS production in DHA-treated cells are shown in Fig 
4.5(a). Compared to control, significant increase in ROS production in the DHA-treated 
cells was observed from 30 min onwards and increased steadily till 4 hours. Fig 4.5(b) 
shows the dose-dependant increase in ROS generation in cells treated with increasing 
concentrations of DHA for 1 hour. Pre-treatment with antioxidants, α-tocopherol (50 µM) 
and N-acetyl-cysteine (5 mM) for 1 hour, inhibited the ROS generation by DHA. α-
tocopherol was more potent than NAC in inhibiting the ROS increase  (Fig 4.5a). 
 
4.2.2.2 Effect of antioxidants and H2O2 on DHA-induced MAPK activation 
 As ROS is a known activator of MAPKs, we attempted to explore whether the 
MAPK activation, especially that of JNK was induced by ROS. Cells were pre-incubated 
with antioxidants NAC (5 mM) and α-tocopherol (50 µM) for 1 hour, and followed by 
100 µM DHA for another 1 hour. As shown in Fig 4.6 (a), both antioxidants did not 
significantly affect JNK activation triggered by DHA stimulation. However, ERK 
phosphorylation was blocked by the antioxidants.  
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 The role of ROS in MAPK activation was further assessed by treating HT-29 cells 
with 100 µM H2O2 and the activation of MAPKs was examined. As shown in Fig 4.6 (b), 
H2O2 alone did not activate JNK, but potentiated the DHA-induced JNK activation. In 
contrast, H2O2 incubation induced strong ERK activation and further enhanced the ERK 
activation by DHA. These data demonstrate that ROS signal predominantly through the 
ERK pathway but is not involved in the initial activation of the JNK pathway. 
 
4.2.2.3 Effect of antioxidants on DHA-induced cell death   
 
 To examine whether enhanced ROS production was responsible for the cytotoxic 
effects of DHA, HT-29 cells were first pre-incubated with antioxidants NAC (5 mM) or 
α-tocopherol (50 µM) for one hour followed by treatment with 100 µM DHA for 48 
hours. As shown in Fig 4.7, neither NAC nor α-tocopherol caused cell death at the 
concentrations used. Upon preincubation with these antioxidants, there was slight 
protection from DHA induced cell death but the difference was not significant. At the 
concentrations of NAC and α-tocopherol used, the ROS generation was significantly 
inhibited, as shown in Fig 4.5. In spite of ROS inhibition DHA alone was able to inhibit 
the growth of HT-29 cells. This implies that though DHA generates ROS but it induces 
apoptosis via a ROS-independent mechanism. 
 
4.3 DISCUSSION 
 In this study we first showed that DHA activates the MAPK signaling kinases, 






















































0            15            30            60          120    240       mins







Fig 4.1 DHA activates MAPKs in HT-29 cells (a) Time-course of MAPK 
activation. Cells were treated with 100µM DHA for 0,15,30, 60, 120 and 
240 minutes respectively. (b) Dose-response of MAPK activation after 1 
hour DHA (0, 50, 100 and 200 µM) treatment. Activation of JNK was 
detected by phosphorylation of c-jun. Activation of p38 and ERK were 
assessed by immunoblotting with the respective phospho-MAPK antibodies. 
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Fig 4.2 DHA activates JNK as determined by in vitro immunocomplex assay. (a) 
Time-course of JNK activation. Cells were treated with 100µM DHA for 
0,15,30, 60, 120 and 240 minutes respectively. (b) Dose-response of JNK 
activation after 1 hour DHA (0, 50, 100 and 200 µM) treatment. Immunoblot 






























Control      DHA      DHA DHA DHA
+SP           +SB         +PD
(a)
(b)
Fig 4.3 Effect of inhibiting MAPK pathways on DHA-induced cell death. HT-29 cells 
were pretreated with SP600125 (JNK inhibitor), SB203580 (p38 inhibitor) or 
PD98059 (ERK inhibitor) for 1 hour followed with 100 µM DHA treatment for 
48 hours. (a) Cell viability assessed by MTT assay (b) PARP cleavage as seen 
by immunoblot. Values are mean ± SD (n=3) * p <0.05 compared to DHA 







































































Fig 4.4 Effect of DHA treatment on cells transfected with DN-JNK1 and DN-JNK2 
vectors or the empty vector pcDNA. 48 hours after transfection cells were 
treated with DHA 100 uM. (a) Phosphorylation of c-jun was assessed after 1 
hr of DHA treatment. (b) After 48 hrs morphological changes were examined 
by fluorescence microscopy (arrows depict dead cells) (c) Quantitative result 
of cell death in transfected cells. *p<0.05 compared to control group.
*
p-c-jun
Control        pcDNA DN-JNK1
DN-JNK2

































































































Fig 4.5 DHA-induced generation of ROS in HT-29 cells (a) Time-course. Cells were 
treated with 100µM DHA for 15, 30, 60, 120 and 240 minutes respectively. 
(b) Dose-response.  Cells were exposed to 0, 50, 100 and 200 µM DHA for 1 
hour. Cells were pretreated with 50 µM α-tocopherol or 5 mM NAC for 1 hr 
before treatment with DHA. Values are mean ± SD (n=3) * p <0.05 



























































Ctrl             H2O2 DHA        DHA+H2O2
(a)
(b)
Fig 4.6 Role of ROS in DHA-induced MAPK activation. (a) HT-29 cells were pretreated 
with α-tocopherol (VE) or NAC for 1 hour, followed with 100 µM DHA. (b) Cells 
were treated with 100 µM DHA and 100 µM H2O2 for 1 hour . Phosphorylation of 
MAPKs was detected by immunoblotting with respective phospho-MAPK 











































































Fig 4.7 Effect of antioxidants on DHA-induced cell death. HT-29 cells were 
pretreated with 50µM α-tocopherol for 1 hour followed with 100 µM DHA 
treatment for 48 hours. (a) Cell viabililty assessed by MTT assay (b) PARP 
cleavage as seen by immunoblot. Values are mean ± SD (n=3). Western blot 
data shown is representative of 3 independent experiments
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of DHA exposure, JNK and p38 activation were relatively delayed. Activation of MAPKs 
by DHA raises questions as to the primary signals that trigger these kinase cascades. Our 
results indicate that formation of ROS by DHA may play an important role in the 
activation of ERK, whereas JNK activation may require a distinct mechanism. Previous 
studies have suggested that DHA undergoes lipid peroxidation and also generates ROS 
(Das, 1991). Therefore ROS and peroxides have been implicated in the action of DHA 
and other PUFAs. In our experiments, consistent with earlier reports (Watkins et al., 
1998), we found that DHA increases the intracellular ROS. Furthermore, DHA caused a 
dose-dependent increase in ROS generation as well as MAPK activation, which gives the 
impression that ROS generation and MAPK activation are correlated. Instead, 
pretreatment with potent radical scavengers such as NAC or α-tocopherol before 
exposure to DHA, substantially reduced ERK activation only but did not affect JNK 
activation. Thus, we hypothesize that DHA-induced oxidative stress is responsible for 
ERK activation. This notion is also supported by the observation that H2O2 itself 
activated ERK and enhanced the ERK activation by DHA. In contrast, oxidative stress is 
not the primary signal responsible for the activation of JNK by DHA. H2O2  itself did not 
activate JNK, but it may play a role in sensitizing  the cells to JNK activation, as 
treatment with H2O2 at concentrations that did not activate JNK, potentiated the JNK 
activation by DHA (Fig 4.6). The signaling cascade by which DHA activates JNK still 
remains to be determined.  
 JNK is activated in response to a variety of stress, including UV, hyperosmolarity, 
toxins, ischemia, heat shock, anticancer drugs and inflammatory cytokines (Wada and 
Penninger, 2004). The activation of JNK by a number of stressors appears to require 
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ROS, suggesting it to be the common factor in many pathways (Zhang and Chen, 2004) 
However, for some stimuli, the activation of MAPKs does not require ROS (Adler et al., 
1995; Yu et al., 1997). The difference in the upstream regulators of MAPKs may explain 
the difference of ERK and JNK activation in our study.  JNK is regulated by the upstream 
kinases MKK4 and MKK7, whereas ERK is regulated by MEK1 and MEK2. Although 
MKK4 and 7 are structurally related to MEK1 and MEK2, MEKs do not activate JNKs, 
and conversely MKKs do not activate ERKs. This implies that parallel and independent 
signaling cascades exist for ERK and JNK activation (Su and Karin, 1996) to allow for a 
functional dichotomy among kinase cascades. 
 The physiological consequences of activation of different MAPKs in response to 
DHA are variable. ERKs have been commonly associated with cell growth, proliferation, 
or transformation. In our study, however, selective blockade of ERK did not affect the 
cell viability. Furthermore, though arachidonic acid and H2O2 also stimulated ERK, but 
they did not stimulate cell proliferation (data not shown), suggesting that ERK does not 
play a significant role in cell proliferation in HT-29 cells. Unlike ERKs, JNKs mediate 
more diverse cellular processes, depending on the stimuli. We found that the apoptotic 
effect of DHA was significantly diminished by the specific JNK inhibitor SP600125 or 
by the ectopic expression of two dominant-negative JNKs (DN-JNK1 and DN-JNK2). 
These results suggest that JNK has a critical pro-apoptotic role in mediating the growth 
inhibitory effects of DHA. The mechanism that accounts for the pro-apoptotic actions of 
JNK has not been completely elucidated. While it is known that JNK is related to 
apoptotic signaling in many systems (Cano and Mahadevan, 1995), it was also found to 
induce cell proliferation and differentiation (Westwick et al., 1995; Sakata et al., 1995). It 
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is now hypothesized that JNK is not always involved in apoptosis, but rather regulates 
apoptosis in a signal-specific, and perhaps cell type-dependent manner (Wada and 
Penninger, 2004). 
 In conclusion, the present study shows for the first time that DHA is capable of 















































DHA INHIBITS TUMOR NECROSIS FACTOR-α INDUCED 
CYCLOOXYGENASE-2 EXPRESSION THROUGH  
THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ 
PATHWAY 
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5.1 INTRODUCTION   
Cyclooxygenase (COX) is present in two isoforms COX-1 and COX-2. While 
COX-1 is thought to be responsible for the “housekeeping” prostaglandin production, 
COX-2, on the other hand, is highly inducible and its expression is elevated by a variety 
of stimuli, including mitogens, tumor promoters and cytokines (DuBois et al., 1998). 
Several studies have established that COX-2 overexpression promotes the progression of 
a variety of human malignancies, including cancer of the colon. Increased COX-2 levels 
provide tumor cells with growth and survival advantages, including resistance to 
apoptosis and increased invasiveness or angiogenesis (Cianchi et al., 2001; Tang et al., 
2002). That COX-2 inhibition might be an important mechanism of tumor inhibition has 
been indicated in studies using mice with manipulation of the COX-2 gene.  COX-2 null 
mice, even with a mutation in the APC gene, showed a significant reduction in intestinal 
polyps, whereas wild-type COX-2 overexpression enhanced tumorigenesis (Oshima et 
al., 1996).  
Unsaturated fatty acids and their metabolites are known to bind and activate 
peroxisome proliferator-activated receptors (PPARs). PPARγ and related isoforms, 
PPARα and PPARδ, constitute a family of nuclear hormone receptors with important 
roles in regulation of fatty acid metabolism (Kersten et al., 2000). However fatty acids 
are also able to regulate expression of other genes involved in stress, inflammation, 
growth and differentiation through these PPARs (Khan and Vanden Heuvel, 2003). 
Recently it was reported that PPARγ is expressed in malignant cells and that ligand 
activation affects malignant cell proliferation and growth (Brockman et al., 1998; Sarraf 
et al., 1998b; Rumi et al., 2001). However, it is uncertain whether PPARγ is indeed a 
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molecular target of this effect, because different PPARγ ligands are also known to have 
receptor-independent actions (Okano et al., 2003; Cippitelli et al., 2003).   
Numerous animal studies have demonstrated that a fish-oil diet, rich in DHA, 
results in a significant decrease in COX-2 expression both in the colonic mucosa and in 
tumors. The decreased COX-2 expression correlates with a decreased tumor incidence 
and lower tumor multiplicity in animals (Singh et al., 1997; Rao et al., 2001). The fact 
that DHA acts as a PPARγ ligand and can modulate COX-2 expression implies a possible 
role of PPARγ in DHA mediated COX-2 regulation.  However, only few studies have 
looked into the relationship between DHA and COX-2 in colon cancer cell lines. In the 
present study, we examine the ability of DHA in regulating COX-2 expression in HT-29 





5.2.1 DHA inhibits TNF-α induced COX-2 and NF-kB activation 
  
 As shown in Fig 5.1(a), TNF-α (20ng/ml) induced COX-2 protein expression in 
HT-29 cells. The data also suggest that pre-treatment with DHA for 6 hours suppressed 
the TNF-α–induced COX-2 in a dose-dependent fashion. This effect was more obvious 
with a higher concentration of DHA (200 µM).  
 NF-κB is one of the regulators of COX-2, and TNF-α is also known to increase 
the transcriptional activity of NF-κB. To determine whether DHA could prevent the 
TNF-α induced NF-κB activity, we determined the NF-κB activity utilizing the reporter 
gene luciferase assay. HT-29 cells were transfected with the pNF-κB-luc construct. 24 
hours after transfection, cells were treated with DHA for 6 hours. NF-κB was then 
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stimulated by incubation with TNF-α for another 6 hours.  As shown in Fig 5.1(b), TNF-
α induced a 6-fold increase in the luciferase activity. DHA itself did not inhibit the basal 
luciferase activity but DHA pretreatment dose-dependently inhibited NF-κB luciferase 
activity induced by TNF-α. This suggests that the inhibition of TNF-α induced COX-2 
expression by DHA is at least in part due to its inhibitory effect on TNF-α induced NF-
κB activation. 
 
5.3.2 DHA induces transcriptional activation of PPARγ  
 HT-29 cells are known to express PPARγ and fatty acids have been reported to 
bind to PPARγ.  To explore if DHA binding increased the transcriptional activity of 
PPARγ, luciferase reporter gene assay was performed. HT-29 cells were transiently 
cotransfected with an acyl-CoA oxidase promoter luciferase reporter plasmid containing 
a PPRE-activation sequence. The transcriptional activity of a β-galactosidase construct 
was used as an internal control.  Ciglitazone, a selective agonist for PPARγ, served as a 
positive control. Fig 5.2 shows that DHA activated the PPARγ transcriptional activity, 
but a significant increase was seen only at a high concentration of 200 µM.  
 ERK is reported to regulate PPAR activity. Previously we showed that DHA 
activated MAPKs (chapter 4). To investigate whether the activation of ERK affected the 
transcriptional activity of PPARγ, HT-29 cells were pretreated with the ERK inhibitor, 
PD98059 for 1 hour and then treated with DHA. As shown in Fig 5.3, inhibition of ERK 
by PD98059 increased the PPARγ transcriptional activity. This result shows that ERK 
activation by DHA interferes with its activation of PPARγ. 
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5.3.3 DHA regulates COX-2 expression and NF-κB activation through a PPARγ- 
dependent pathway 
To further evaluate the role of activation of PPARγ by DHA in regulating NF-κB 
transcription and COX-2 expression, functional PPARγ was abrogated by transfection 
with 1µM PPARγ anti-sense oligonucleotides. Control cells were transfected with the 
PPARγ sense oligonucleotides. The expression of PPARγ was then analysed by western 
blotting. As shown in Fig 5.4(a) HT-29 cells transfected with antisense oligos showed 
reduced PPARγ expression compared with cells that received sense oligos. The results of 
downregulation of PPARγ on COX-2 expression and NF-κB activation in the transfected 
cells are shown in Fig 5.4(b) and (c). Panel (b) shows that DHA inhibited NF-κB in cells 
transfected with sense oligos only, i.e. among cells with a functional PPARγ. On the 
other hand, DHA was unable to inhibit the TNF-α induced NF-κB transcription and 
consequently the COX-2 expression in cells transfected with anti-sense oligos, as shown 
in panel (c). These results show that PPARγ is involved in the inhibition of NF-κB and 
COX-2 by DHA. 
 
5.3.4 DHA induces apoptosis in colon cancer cells by a PPARγ-independent 
mechanism. 
 To investigate whether PPARγ is also involved in DHA-induced apoptosis, 
PPARγ was either blocked pharmacologically by Bis-phenol A diglycidyl ether 
(BADGE), a selective and irreversible inhibitor of PPARγ or downregulated by 
transfection with PPARγ antisense oligonucleotides as described in section 5.3.3. After 
48 hours of incubation with DHA, cell viability was measured by the MTT assay. As 
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shown in Fig 5.5(a), co-treatment with 20 µM BADGE did not alter cellular proliferation 
compared to cells treated with DHA. Consistent with this result, downregulation of 
PPARγ by transfection of anti-sense PPARγ oligos did not rescue the cells from DHA-
induced apoptosis. Fig 5.5 (b) shows that there was no difference in DHA-induced cell 
death in the sense and anti-sense transfected oligos. Taken together, these data indicate 
that DHA-induced apoptosis is mediated through a PPARγ-independent pathway. 
 
5.4 DISCUSSION 
 In the present study we showed that DHA inhibits the induction of COX-2 
expression caused by TNF-α in HT-29 colon cancer cells. TNF-α is a proinflammatory 
cytokine involved in oncogenesis, inflammatory and stress responses (Mannel and 
Echtenacher, 2000). Increased expression of TNF-α  has been found in the colon tissues 
of patients with inflammatory bowel disease and colon cancer (Reimund et al., 1996; 
Louis et al., 2000; Hardwick et al., 2001). Cell-mediated immune responses of 
inflammatory cytokines, including TNF-α, have been hypothesized to play a crucial role 
in the progression from precancerous colon polyps to malignant colorectal cancer 
(Lofberg, 2003). At the molecular level, a key role in the process that links inflammation 
to cellular transformation seems to be caused by the activation of COX-2 (Baldassarre et 
al., 2004). COX catalyzes the conversion of arachidonic acid to prostaglandins which 
participate in normal growth responses and in aberrant cellular growth and proliferation, 
including carcinogenesis. The connection between COX expression and carcinogenesis 
was first implicated in studies that demonstrated the efficacy of COX inhibitors to reduce 
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Fig 5.1 Inhibitory effect of DHA on TNFα induced COX-2 expression and NF-κB
activation in HT-29 cells. (a) Cells were treated with DHA (50,100,200 µM ) 
for 6 hours and then stimulated with TNFα (20 ng/ml) in the presence of 
DHA. After 6 hours, cell lysates were analysed for COX-2 by 
immunoblotting. (b) Cells were transfected with pNF-κB-luc vector for 24 
hours, followed by pre-treatment with DHA for 6 h. The luciferase activity 
was measured after 6 hours of TNFα exposure. The values are mean ± SD 
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Fig 5.2 DHA induces transactivation of PPAR-response element (PPRE) in HT-29 
cells. Cells were transfected with the PPRE-driven luciferase reporter 
construct. 24 hours after transfection, cells were treated with different 
concentrations of DHA (50, 100, 200µM) for 6 hours and the luciferase 
activity was determined. Values are means ±SD (n=3). 








































































DHA + PD 40uM
Fig 5.3 ERK inhibits DHA-induced transactivation of PPAR-response element 
(PPRE) in HT-29 cells. Cells were transfected with the PPRE-driven 
luciferase reporter construct. 24 hours after transfection, cells were pre-treated 
with 40µM PD98059, the specific ERK inhibitor for 1 hour, followed by DHA 
treatment (50, 100, 200µM). After 6 hours the luciferase activity was 
determined. Values are means ±SD (n=3). * p<0.05 compared to control. # 
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sense anti-sense
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TNFα (20ηg/ml)         +         +                +       +
DHA 200uM                - +            - +
TNFα (20ηg/ml)          +            +           +           +
Fig 5.4 The effects of downregulation of PPARγ expression on NF-κB activation and 
COX-2 protein expression. HT-29 cells were transfected with PPARγ sense 
oligonucleotides or PPARγ antisense oligonucleotides (a) 24 hours after 
transfection, expression of PPARγ was seen by immunoblotting. Transfected 
cells were then treated with TNFα for 6 hours with or without pretreatment 
with 200 µM DHA for 6 hours. (b) NF-κB activation was measured by the 
luciferase assay (c) COX-2 expression was seen by immunoblotting. *p<0.05 

















































Fig 5.5 Effect of PPARγ inhibition on DHA-induced cell death. In HT-29 cells, 
PPARγ was inhibited by (a) co-treating cells with 20 µM BADGE, a PPARγ
antagonist, or (b) transfecting cells with PPARγ antisense oligonucleotides. 
Cells were then treated with 200 µM DHA for 48 hours and cell viability was 
assessed by the MTT assay. Values are the means ±SD of 3 independent 





animal models of colon cancer (Marnett, 1992). A variety of evidence gathered from 
epidemiological, whole animal, and cellular studies indicate that COX-2 is upregulated in 
colorectal tumors and that the loss of regulation occurs early in carcinogenesis (Marnett 
and DuBois, 2002; Reddy and Rao, 2002). 
 Unstimulated HT-29 colon cancer cells have a low basal level of COX-2 but 
COX-2 protein expression is readily induced by incubation with TNF-α. Our results 
demonstrate that pre-incubation with DHA, prevented the TNF-α induced COX-2 
expression. The anti-inflammatory role of DHA in the immune system is well known (De 
Caterina et al., 2000; Hong et al., 2003) and is believed to be due to interference with the 
arachidonic acid metabolism. However, in vitro studies show that in cancer cells the 
effect of DHA on COX-2 is quite variable. Unsaturated fatty acids, including DHA, 
induced COX-2 expression in mammary epithelial cells by activation of the PPAR 
pathway (Meade et al., 1999). In contrast, in monocyte/macrophage cells DHA inhibited 
the constitutive and lipopolysaccharide (LPS) stimulated COX-2 expression by acting on 
the Toll-like Receptor 4 (∆Tlr4) (Lee et al., 2001). In the colon cancer cell line HCA-7, 
DHA acts synergistically with the selective COX-2 inhibitor celecoxib to inhibit  the 14C-
arachidonic acid metabolism mediated by COX-2 (Swamy et al., 2004). However, the 
mechanism of interference of DHA in cytokine-induced COX-2 upregulation in colon 
cancer still remains unexplored. 
 To further elucidate the mechanism of the inhibitory effect of DHA on COX-2, 
we explored whether DHA modulated the activity of upstream regulators of COX-2. 
Nuclear transcription factor-κB (NF-κB) is a ubiquitous transcription factor that governs 
the expression of various important genes, including COX-2. NF-κB also regulates the 
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expression of cellular genes involved in inflammatory response, cell immunity and 
apoptosis, thus contributing to oncogenesis and tumor escape from immune surveillance 
(Karin and Lin, 2002). Our findings show that DHA inhibited NF-κB activation, 
upstream of COX-2 which could be responsible for the decrease in COX-2 protein 
expression seen in TNF-α treated colon cells. Consistent with our results, DNA 
microarray has identified the COX-2 and NF-κB genes as one of the targets of DHA in 
the Caco-2 cell line (Narayanan et al., 2003b). 
 Unsaturated fatty acids are ligands of PPARγ (Yu et al., 1995; Forman et al., 
1996). In this set of experiments, we first showed that binding of DHA to PPAR results in 
transactivation of PPRE, as shown by the reporter gene luciferase assay in Fig 5.3. The 
activation of DHA was evident at high concentrations only, consistent with the fact that 
polyunsaturated fatty acids are weak ligands of PPARγ, compared to the more selective 
ones. In addition to being regulated by ligand binding, PPARγ activity is modulated by 
phosphorylation. Activation of MAPKs is reported to decrease the transcriptional activity 
of PPARγ by increasing its phosphorylation (Camp and Tafuri, 1997; Hsi et al., 2001). 
With the use of selective MAPK inhibitors, we demonstrate here that ERK activation by 
DHA interferes with its transcription of PPARγ .When cells were treated with the specific 
ERK inhibitor PD98059, the DHA-induced transcriptional activity of PPARγ increased. 
This suggests that DHA acts not only as an agonist of PPARγ but also influences PPAR 
transcriptional activity independent of receptor binding. The activation of MAPK activity 
induced by DHA seems to be independent of PPARγ-mediated transcription because of 
two reasons. First, the DHA induced MAPK activation occurred within 1 hour and is too 
rapid to account for new protein synthesis. Secondly, DHA concentration of less than 100 
 78
µM was able to stimulate MAPK activity, but concentration higher than 100 µM was 
required for PPARγ activation.  
 We further showed that activation of PPARγ by DHA plays a crucial role in the 
regulation of NF-κB. When the functional transcriptional activity of PPARγ was 
abrogated using anti-sense PPARγ oligos, the ability of DHA to inhibit TNF-α induced 
NF-κB transactivation, and consequently COX-2 was significantly reduced. This shows 
that a functional PPARγ is involved in the inhibitory effect of DHA on COX-2. Similar to 
DHA, other PPARγ ligands have also been reported to exert anti-inflammatory effects by 
blocking the activation of NF-κB and AP-1 (Straus et al., 2000). 15dPGJ2, an 
endogenous PPARγ ligand, has also been shown to inhibit the LPS and interleukin-1β 
(IL-1β)–induced expression of COX-2  by interfering with the NF-κB and AP-1 signaling 
pathway (Subbaramaiah et al., 2001). However, the role of PPARγ ligands in COX-2 
regulation is quite controversial. In mammary and colonic epithelial cells, DHA and other 
PPAR ligands enhanced COX-2 expression, presumably through PPARα (Meade et al., 
1999). Nevertheless, it has been demonstrated that the activation of PPARγ did not affect 
the COX-2 expression in HT-29 cells (Lefebvre et al., 1998). In contrast, Yang and 
Frucht, (2001) reported that the PPARγ ligand ciglitazone, inhibited COX-2 in the same 
cell line. This discrepancy may be due to the difference in the experimental protocols of 
the two groups. In the Lefebvre experiments, COX-2 expression was examined 24 hours 
after PPARγ activation, but Yang showed that inhibition of COX-2 does not occur until 
48 hours after treatment. Our results show that in HT-29 cells, DHA does not affect the 
basal COX-2 expression, but through PPARγ activation, attenuates the inducible COX-2 
which may be overexpressed in response to inflammatory cytokines. 
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 We then tried to explore if PPARγ was involved in DHA-induced cell death. Our 
results show that inhibition of PPARγ does not protect cells from DHA-induced 
apoptosis. This implies that apoptosis in DHA-treated cells occurs by a PPARγ-
independent mechanism. Thus DHA in colon cancer cells acts as a PPARγ agonist, but 
functions through PPARγ-dependent and –independent pathways that result in variable 
biologic effects. Our results, when taken into consideration with animal studies, may 
explain the anti-tumor effect of PPARγ activation. When treated with azoxymethane to 
induce polyps in the colon, mice lacking a functional allele of PPARγ had a significant 
increase in the incidence of colon cancer compared with wild-type mice. However, there 
was no difference in the progression of polyps when wild-type and PPARγ mutant mice 
were compared (Girnun et al., 2002). This implies that PPARγ acts early as a tumor-
suppressor; but once tumor formation or an initiating event has occurred, PPARγ has a 
limited role in controlling cell proliferation. Thus, DHA by activating PPARγ may have a 













DISCUSSION AND CONCLUSIONS 
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 Cancer of the colon is the second most common malignancy in the developed 
world (Parker et al., 1997), and is one of the leading causes of cancer death in the 
developed countries, including Singapore (Cancer incidence in five continents. Volume 
VII). The incidence of colon cancer among Singaporeans is one of the highest in the 
world, accounting for 15.9 % of all cancers among Singapore males, and 14.9% among 
Singapore females (Chia KS et al., 2000). The etiology of colon cancer is complex and 
involves both genetic as well as environmental factors. Among the environmental factors, 
dietary factors play an important role and dietary fats have been linked to the risk of 
colon cancer. It appears that apart from the quantity of fat, the type of fat is also 
important in determining the course of the disease. Epidemiological studies indicate that 
populations with a high intake of n-3 PUFAs have a lower risk of developing colon 
cancer (Caygill et al., 1995). The results of animal studies also demonstrate that the 
consumption of n-3 PUFAs can inhibit the growth and frequency of tumors (Reddy, 
1994). But in spite of ample evidence of the beneficial effects of n-3 PUFAs, the 
mechanism of their anticarcinogenic activities is not completely understood. In this study 
we tried to explore the mechanisms which could explain the chemotherapeutic and 
chemopreventive role of DHA in colon cancer. 
 
6.1 Chemotherapeutic actions of DHA  
Apoptotic effects of DHA have been reported in several cancer cell lines, 
including colon cancer (Shiina et al., 1993, Calviello et al., 1998, Minami et al., 1996, 
Tsai et al., 1998). Our results also show that the growth inhibitory effect of DHA in HT-
29 cells is due to apoptosis (Fig 3.4 to 3.6). Further, the apoptotic effect of DHA is 
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dependent on the activation of caspase-3 (Fig 3.7 and 3.8). Modulation of mitochondrial 
functions and release of cytochrome c may also be involved in DHA-induced apoptosis 
(Arita et al., 2003). It has been hypothesised that the interaction of fatty acid metabolites 
with the adenine nucleotide translocase of the mitochondrial inner membrane, forms an 
additional route for the dissipation of the proton gradient (Wojtczak and Wieckowski, 
1999), thus resulting in the disruption of mitochondrial functions. Another possible 
explanation for the cytotoxicity of PUFAs is believed to be the surfactant nature of the 
fatty acid molecules. Because PUFAs interact with cellular membranes, it might directly 
affect the stability and functions of the membranes and modulate membrane bound 
enzymes and/ or phospholipids, thereby initiating a sequence of events leading to 
apoptosis (Brecher, 1983). 
 Our results show that among the PUFAs, DHA was the most potent in 
inhibiting growth (Fig 3.1). Differences in the ability of DHA and other PUFAs to induce 
apoptosis could be related to their ability to incorporate into the phospholipid bilayer. On 
exogenous supplementation, n-3 PUFAs are readily incorporated into the phospholipid 
bilayer and this change occurs at the expense of arachidonic acid. Differential β-oxidation 
and assimilation into neutral lipids may also explain the differences in the effects of n-3 
and n-6 PUFAs (Jump, 2002). Among the n-3 PUFAs, DHA seems to be more important 
than EPA, as cells tend to conserve DHA over EPA when placed in a fatty acid-deficient 
medium (Ghioni et al., 1997). In the normal colon mucosa,  the membrane concentration 
of DHA is several-fold higher than that of EPA (Calviello et al., 1998), which may 
explain the higher responsiveness of colon cells to DHA. 
 83
 It has been reported that the tumoricidal  action of PUFAs appears to be 
related to their ability to increase free radical generation and lipid peroxidation in tumor 
cells (Das, 1991b). This hypothesis is supported by the observation that antioxidants can 
prevent the tumoricidal action of these long chain fatty acids (Das, 1991a; Sagar et al., 
1992). However this does not seem to be general phenomena. Our results showed that 
preincubation with the antioxidants NAC or α-tocopherol, did not significantly affect the 
DHA-induced cytotoxicity. Our results are supported by the observation that in Ramose 
leukemia cells, apoptosis induced by EPA was unaffected by vitamin E (Finstad et al., 
1998). Similarly in HepG2 cells, conjugated linoleic acid induced apoptosis by a change 
in fatty acid metabolism and not by lipid peroxidation (Igarashi and Miyazawa, 2001). 
Sprague-Dawley rats fed with DHA-rich fish oil, showed an increase in the phospholipid 
unsaturation index and ROS generation but fish oil alone did not induce apoptosis in 
colonocytes (Hong et al., 2002).   
The presence of unsaturated bonds in PUFAs makes them susceptible to 
oxidation. Therefore, the lipid peroxidation would be dependent on the degree of 
unsaturation, rather than the PUFA itself. In this regard, arachidonic acid has a high 
unsaturation index, similar to that of EPA. Contradictory to the proposed peroxidation 
hypothesis, generation of ROS by arachidonic acid did not parallel its antiproliferative 
effect (data not shown). Similarly, diets rich in different PUFAs conferred the same 
degree of lipid unsaturation in Apc Min+/- mouse tissues but had significantly different 
effects on tumorigenesis (Petrik et al., 2000a; Petrik et al., 2000b). Taken together, these 
studies indicate that though lipid peroxidation seems to be involved, cells may either deal 
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with oxidative stress in different ways, or that the production of ROS is not the only 
means for PUFA induced cytotoxicity and that other mechanisms may also be involved. 
 The c-Jun N-terminal kinases (JNKs) phosphorylate and activate members of the 
activator protein-1 (AP-1) transcription factor family and other cellular factors implicated 
in regulating altered gene expression, cellular survival and proliferation in response to 
cytokines and growth factors, noxious stimuli and oncogenic transformation (Davis, 
2000). Our results demonstrate that DHA stimulates activation of JNK, and that in HT-29 
cells JNK has a pro-apoptotic role in mediating the effects of DHA. This was shown by 
inhibiting the JNK activity with SP600125 or by the ectopic expression of mutant JNK 
which resulted in attenuation of the cytotoxic effect of DHA. Though JNK is known to 
have a proliferative effect in some cell systems, the involvement of JNK in various forms 
of cell death has also been extensively documented (Davis, 2000). It is believed that JNK 
is required for apoptotic cell death elicited by environmental stress stimuli such as 
oxidative stress and UV. For instance, JNK1 -/- and JNK2 -/- null cells are resistant to 
UV induced apoptosis (Tournier et al., 2000). In the immortalized and cancer cells, JNK 
cascades probably change gene expressions and set the cellular susceptibility to apoptotic 
stimuli. The role of JNK as a tumor suppressor is consistent with the presence of loss-of-
function mutations in JNK pathway components (Jnk3 and Mkk4) in human tumors 
(Kennedy and Davis, 2003). Since ROS have been known to activate MAPK, we 
examined the role of ROS signaling in the activation of JNK.  Interestingly ROS 
signaling seems to have a limited role in the activation of JNK, as down-modulation of 
ROS level did not inhibit activation of JNK (Fig 4.6), suggesting that DHA may activate 
JNK through another mechanism which might be responsible for its pro-apoptotic effects.  
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6.2 The chemopreventive role of DHA 
 Our results show that the inhibitory effect of DHA on TNFα–induced COX-2 
expression was dependent on PPARγ. The PPAR family of receptors were the first 
nuclear receptors to be examined as a fatty acid receptor. Though PPARs play a 
fundamental role in dietary fat storage and catabolism (Kersten et al., 2000),  evidence is 
emerging that PPARs and the γ isoform in particular, are important in regulating 
pathways beyond energy homeostasis (Kliewer and Willson, 1998). PPARγ may be 
important in modulating the intestinal inflammatory response (Su et al., 1999; Nakajima 
et al., 2001) as well as regulating the growth of epithelial cells (Lefebvre et al., 1999). 
However, the role of PPARγ in colon cancer attracted some controversy when it was 
shown that PPARγ agonists may increase colon polyps in mice that are predisposed to 
intestinal adenomas because of a mutation in the adenomatous polyposis coli (Apc) gene 
(Saez et al., 1998). Our results might therefore have important clinical implications as 
they show the effects of the interaction of PUFAs with  PPARγ in HT-29 cells, which 
also harbor a mutated Apc gene and express a truncated APC protein (Hsi et al., 1999). 
 Though it is well known that PUFAs are natural ligands of PPARs, several pieces 
of indirect and direct evidence suggest that select anticancer activity of PPARγ ligands 
could occur independently of PPARγ. Thus in our study we first attempted to show that 
DHA activates PPARγ and then sought to distinguish between the PPARγ-dependent and 
–independent effects of DHA. We showed that on abrogating the functional PPARγ, 
COX-2 expression was affected but the cell viability was not. This implied that the DHA-
induced cell death was independent of the PPARγ and COX-2 pathways. This is in line 
with a previous report that the PPARγ ligand did not induce apoptosis within 48 hours of 
 86
treatment in HT-29 cells (Yang and Frucht, 2001). Further, COX-2 is not involved in 
DHA-induced apoptosis, is supported by the study which shows that n-3 PUFAs 
suppressed tumor cell growth both in nude mice and in culture by cyclooxygenase 
independent pathways (Boudreau et al., 2001).  
 This finding that DHA inhibits TNF-α-induced COX-2 through PPARγ activation 
might explain the chemopreventive effects of DHA as  
(i) Cytokines, including TNF-α and interleukins (IL), are implicated in the etiology of 
inflammatory bowel diseases such as Crohn’s disease which is a risk factor for colorectal 
cancer (Orlando, 2002). In our study we showed that DHA inhibits the actions of TNF-α 
and NF-κB which are known to be pro-inflammatory. 
(ii) COX-2 seems to give a growth advantage only in the early stages of tumorigenesis. 
This was demonstrated in a xenograft tumor model, where COX-2 specifically expressed 
in the non-neoplastic stromal tissues significantly enhanced angiogenesis and tumor 
growth, whereas expression in the neoplastic tissue did not (Williams et al., 2000). 
(iii) Administration of PPARγ agonists reduced pre-malignant intestinal lesions in rats 
treated with the carcinogen azoxymethane (Tanaka et al., 2000). 
 This evidence suggests that the beneficial effects of PPARγ activation and COX-2 
inhibition by DHA may be seen early in the course of colon cancer. Other pathways may 
also be involved in the chemopreventive effects. For instance, n-3 PUFAs can 
differentially reduce membrane localisation and activity of Ras, which is a key 
oncoprotein in the early stages of colorectal cancer (Collett et al., 2001). Thus, the 
findings of our study may explain the chemopreventive role of DHA seen in animal 
studies and epidemiological studies.  
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6.3 Comparison of results from in vitro and in vivo studies 
 The ability to culture tumor cells in the presence of PUFAs over a relatively short 
period of time allows insight into the mechanism of action of these PUFAs. But 
differences exist between the data from in vitro and in vivo studies. The in vitro studies 
do not show a marked difference in the effects of n-3 and n-6 PUFAs. Also, in vitro, a 
wide variety of cell types are affected, while only a few cancer types show a dietary link 
with PUFAs. This difference may be explained by the studies which show that in colon 
cancer, the n-3 PUFAs may have additional effects in vivo. In the gut lumen, DHA 
inhibits the formation of mutagenic secondary bile acids (Rao et al., 1996), and 
diacylglycerol, a phospholipid derived second messenger (Jiang et al., 1996). n-3 PUFAs 
may also affect the disposition of fat and triacylglycerol metabolism (Roche and Gibney, 
2000), thus reducing insulin resistance and tumor promotion (Koohestani et al., 1998).  
Recently it has been suggested that protection against colon tumor growth may be partly 
due to angiogenesis inhibition (Rose and Connolly, 2000). A role for n-3 PUFAs in 
limiting cachexia and increasing survival in murine models of colon cancer has also been 
identified (Tisdale and Dhesi, 1990; Gogos et al., 1998). In addition, PUFAs may also 
limit the invasive and metastatic potential of the tumor by inhibiting cell adhesion and 
motility (Iigo et al., 1997b).  These features are seen in the whole organism and may 
explain the strong evidence of the anticancer effects of DHA as reported in 





6.4 Conclusions  
 Based on the literature, n-3 PUFAs have emerged as anti-carcinogenic agents 
showing potential benefit for colon cancer. In vivo, they show chemopreventive, anti-
proliferative, anti-inflammatory effects and also inhibit angiogenesis and metastasis. 
Although these appear to be disparate actions, they may largely work through common 
mechanisms of cell signaling. In the present study we tried to elucidate the anti-cancer 
mechanism of the n-3 PUFA, DHA, in colon cancer cell lines. Our results can be 
summarized as follows: 
(1) DHA inhibited the growth of the colon cancer cell lines. 
 -  The reduction in cell viability was due to caspase-dependent apoptosis. 
 -  The metabolic conversion of DHA was not required to induce apoptosis. 
(2)  DHA activated the MAPK signaling pathways - JNK, p38 and ERK 
            - DHA-induced apoptosis was dependent on JNK activation. 
            - JNK activation was independent of ROS generation. 
(3) DHA induced ROS formation in the tumor cells 
            - ROS were partially responsible for the ERK activation 
            - DHA-induced cell death was not dependent on its ability to generate ROS in   
colon cells 
(4) DHA inhibits TNFα-induced NF-κB activation and COX-2 expression. 
            - This inhibition is dependent on the activation of PPARγ by DHA. 
            - PPARγ and COX-2 are not involved in the cytotoxicity of DHA. 
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These findings imply that DHA may have chemopreventive benefits in addition to their 
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